Identification of potential inhibitors of cutaneous Melanoma and Non-Melanoma skin cancer cells through in-vitro and in-silico screening of a small library of Phenolic compounds

Samuel T. Boateng,^a Tithi Roy,^a Mercy E. Agbo,^b Sergette Banang-Mbeumi,^a Roxane-Cherille N. Chamcheu,^a Marion Bramwell,^a Long K. Pham,^a Keith E. Jackson,^a Ronald A. Hill,^a Bolni Marius Nagalo,^{c,d} Tatiana Efimova,^{e,f,g} Jean Fotie,^{b*} Jean Christopher Chamcheu,^{a*}

^a *School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana - Monroe, Monroe, LA 71209-0497, USA*

^b *Department of Chemistry and Physics, Southeastern Louisiana University, Hammond, LA 70402-0878, USA*

^c *Department of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA*

^d *The Winthrop P. Rockefeller Cancer Institute, UAMS, Little Rock, AR, USA* ^e *Department of Anatomy and Cell Biology, School of Medicine & Health Sciences, The George Washington University, NW Washington, D.C. 20037, USA*

^f *Department of Dermatology, School of Medicine & Health Sciences, The George Washington University, NW Washington, D.C. 20037, USA*

^g *The George Washington Cancer Center, School of Medicine & Health Sciences, The George Washington University, NW Washington, D.C. 20037, USA*

*** Corresponding author(s):** Jean Christopher Chamcheu, PhD., School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana - Monroe, Monroe, LA 71209-0497, USA. Email: chamcheu@ulm.edu; Phone: 318-342-6820, Fax: 318-342-

Jean Fotie, PhD., Department of Chemistry and Physics, Southeastern Louisiana University, Hammond, LA 70402-0878, USA E-mail: jean.fotie@southeastern.edu; Phone: 985-549-5112, Fax: 985-549-5126.

Keywords: Library screening, Melanoma and non-melanoma skin cancer cells, Anti-cancer activity, Apoptosis, *In silico* target(s) prediction, and Pharmacokinetic and ADMET studies.

Abstract

Melanoma and non-melanoma skin cancers are the most-lethal and commonest forms of skin cancers, that affecting one-fifth of the US population. With the aim of identifying new lead compounds as starting point for attaining cost-effective therapies, a small library of about 90 molecules was screened *in vitro* against A375, SKMEL-28, A431, SCC-12 skin cancer cell lines. About 35 of them, mainly dihydroquinolines, C–C and C–N linked biphenyls, and substituted methylgallate or aniline derivatives, displayed low-micromolar range activities, primarily against the A431 and SCC-12 squamous carcinoma cell lines, with only a handful of these compounds displaying any activity against the A375 and SKMEL-28 melanoma cell lines. Compounds **11** (A431: IC₅₀ = 5.0 μM, SCC-12: IC₅₀ = 2.9 μM, SKMEL-28: IC₅₀ = 4.9 μM, A375: IC₅₀ = 6.7 μM) and **13** (A431: IC₅₀ = 5.0 μM, SCC-12: IC₅₀ = 3.3 μM, SKMEL-28: IC₅₀ = 13.8 μM, A375: IC₅₀ = 17.1 μM) were the most active across all these cell lines. Furthermore, many of the hit compounds showed little to no activity against mammalian nontumorigenic immortalized HaCaT cells, with a far better selectivity index than cisplatin (a well-known anticancer agent used as a positive control). Compounds **11** and **13** significantly and dose-dependently induced apoptosis of SCC-12 and SK-MEL-28 cells as evidenced by the downregulation of Bcl-2 and upregulation of Bax protein expression levels, and by cleaved caspase-3, caspase-9 and PARP levels. Both agents also significantly reduced scratch wound healing, colony formation, and activated expression levels of major cancer molecular targets such as RSK/AKT/ERK1/2 and S6K1. To provide a better attribute profile for each of the hit molecules, in-silico target(s) prediction, pharmacokinetic and ADMET studies are also reported, together with some preliminary structure-activity relationship outlines. The SwissTargetPrediction web-based tool identified CDK8, CLK4, nuclear receptor

ROR, tyrosine protein-kinase Fyn/LCK, ROCK1/2, and PARP, all of which are dysregulated in skin cancers, as likely targets for these hit compounds. Furthermore, the SwissADME web_tool predicted these compounds to exhibit high GI tract absorption, good skin permeation, and a viable biodegradability profile. To summarize, these data highlight the promising anticancer potential of these small molecules leads, warranting further investigation and/or optimization towards obtaining clinical candidates for combatting both melanoma and non-melanoma skin cancers.

Abbreviations used:

ADMET: absorption, distribution, metabolism, excretion, and toxicity; **BCC:** basal cell carcinoma; **CDK:** cyclin-dependent kinases; **COX:** cyclooxygenase; **CDK16:** cyclin-dependent kinase 16; **DMEM:** Dulbecco's modified eagle medium; **DMSO:** dimethyl sulfoxide; **EGCG:** epigallocatechin-3-gallate; **FBS:** fetal bovine serum; **HPLC:** high performance liquid chromatograph; **HRMS:** high-resolution mass spectrometry; **IC₅₀:** half-maximum inhibitory concentration; **IHC:** immunohistochemical; **JAK:** janus kinase; **LC-MS/MS:** liquid chromatography coupled to tandem mass spectrometry; **MAPK:** mitogen-activated protein kinase; **MDM2:** mouse double minute 2 homolog; **MMP9:** matrix metalloproteinase 9; **MS:** mass spectrometry; **mTOR:** mammalian target of rapamycin; **MTT:** 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide; **NAD:** nicotinamide adenine dinucleotide; **NAMPT:** nicotinamide phosphoribosyltransferase; **NF-κB:** nuclear factor κ-light-chain-enhancer of activated B cell; **NMR:** nuclear magnetic resonance; **PARP:** poly (ADP-ribose) polymerase; **PBS:** phosphate buffered saline; **PI3K:** phosphoinositide 3-kinase; **SAR:** structure-activity relationship; **SCC:** squamous cell carcinoma; **SD:** standard deviation; **TGF-β:** transforming growth factor β; **TLC:** thin layer chromatography; **STAT:** signal transducer and activator of transcription.

1. Introduction

Skin cancer is considered one of the most prevalent cancer types globally, with its prevalence and mortality expected to keep growing at alarming rates.^{1,2} Non-melanoma and melanoma skin cancers affect approximately 3 million people globally each year.³ Studies have shown that the lessened ozone layer protection vs. historical levels, resulting in greater human exposure to UVB rays at the Earth's surface, is one of the major risk factors for the development of squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and melanoma, with the incidence of these illnesses, predicted to continue to increase.⁴⁻

⁶ One of the most effective therapeutic approaches at the early stages for skin cancers include misplaced surgical tumor excision^{1,2}; however, surgery can result in disfigurement, requiring skin grafts for covering

the defects, and such surgeries can be quite costly-prohibitively so for some patients.⁷⁻⁹ Arresting proliferation or inducing programmed cell death in proliferating cancer cells is another effective cancer therapy option.¹⁰⁻¹³ Significant advances have been made toward a better understanding of mechanisms through which melanoma and non-melanoma skin cancers are triggered and sustained. Hotspot mutations of the oncogenes BRAF and NRAS are the most common genetic alterations in cutaneous melanoma, and such mutations are known drivers of all melanomas, as mutant BRAF and NRAS can independently activate the downstream MEK1/2-ERK1/2 oncogenic signal transduction pathway.¹⁴⁻¹⁷ Although inhibitors of BRAF and MEK have shown significant survival benefits in clinical trials, the prognostic significance of BRAF and NRAS mutations outside of clinical trials remains unclear.¹⁴⁻¹⁷ The overexpression and activation of V-akt murine thymoma viral oncogene homolog (AKT, also known as protein kinase B)¹¹ and related signaling pathways are also known to be major contributing factors in many cancers, including some lung cancers, esophageal squamous cell carcinomas and various skin cancers.¹⁸ Other signaling pathways, including those involving mitogen-activated protein kinase (MAPK),¹⁹⁻²¹ phosphoinositide 3-kinase (PI3K)-Akt,²²⁻²⁴ mammalian target of rapamycin (*mTOR*),^{22,25,26} nuclear factor κ -light-chain-enhancer of activated B cell (NF- κ B),²⁷ Janus kinase-signal transducer and activator of transcription (JAK-STAT), transforming growth factor β (TGF- β),^{28,29} and Notch are shown to play an important role in skin homeostasis, and in melanoma and non-melanoma cancer progression.¹⁸ Knowledge of these potential drug targets constitutes an important tool towards devising mechanistically novel anti-skin-cancer agents. Despite these remarkable advances in our scientific understanding, current available/validated/approved pharmacological treatments still face severe limitations, in many instances due to the low penetrability of the available drugs into stratum corneum or lesions,^{12,30,31} leading to their inability to reach the tumor cells and tissues well enough to achieve robustly efficacious levels.³² This low bioavailability at the site of action usually requires the administration of higher doses, resulting in skin

irritation or worse, increased severity of side-effects or toxicities.³³⁻³⁵ The emergence of new therapies designed to stimulate the immune system, including immune checkpoint inhibitors (ICIs), in order to promote the immunorecognition and the elimination of tumor cells, has provided new hope for the effective treatment of a wide range of malignancies, such as melanoma, renal cell carcinoma, non-small cell lung cancer (NSCLC), and bladder cancers, to name just a few.^{36,37} Although these agents have dramatically improved the cancer prognosis for many patients; these treatments are unfortunately associated with significant side-effects, due to an uncontrolled activation of the immune system. Furthermore, only about 50% of patients with these cancers currently respond to ICI immunotherapy, the precarity which of course argues for continued search for novel potential targets,^{37,38} in hopes of devising new, effective and economically sustainable therapies against melanoma and non-melanoma skin cancers.

As part of a continuing effort to introduce new-molecular-scaffold-based entities with low toxicity and enhanced efficacy into the cutaneous cancer treatment pipeline, our research groups have shown that simple phenolic compounds such as a green tea polyphenol, namely (-)-epigallocatechin-3-gallate (EGCG), could modulate human keratinocyte-induced responses and alleviate imiquimod-induced murine psoriasiform dermatitis.^{39,40} We recently showed that fisetin and its analogs inhibit the PI3K/Akt/mTOR and MAPK and effector pathways in organotypic human inflammatory skin and melanoma models,^{41,42} as well as c-Kit, CDK2 and mTOR kinases in melanoma and non-melanoma skin cancers.²⁵ Herein, we report the *in vitro* screening of a small library of about 90 compounds previously synthesized in our laboratory against melanoma (A375 and SKMEL-28) and non-melanoma (A431 and SCC-12) skin cancer cell lines. *In-silico* studies were carried out, aimed at target(s) prediction and at predicting pharmacokinetic and ADMET (absorption, distribution, metabolism, excretion, and toxicity) attributes for selected hit molecules. Mode-of-action explorations by way of in-vitro cellular and molecular biological methods were

conducted for the two most active compounds (**11** and **13**). We report preliminary structure-activity relationship, prospective targets and discuss these in the context of other pertinent pharmacologic and biopharmaceutic aspects of our findings.

2. Results and discussion

2.1. Chemistry

The focus here is exclusively on the synthesis of 35 compounds from the library that displayed a relevant behavior during either the *in vitro* biological or the *in silico* studies. As such, compounds **1** and **2** are methyl 3,4,5-trimethoxybenzoate derivatives closely related to methyl gallate and were prepared through electrophilic bromination and nitration, respectively, as illustrated in **Scheme 1**.⁴³

Scheme 1: Synthesis of methyl 3,4,5-trimethoxybenzoate derivatives⁴³

4-cyclohexenylaniline derivatives (**3** and **4**) were obtained by reacting the corresponding aniline derivative with cyclohexanone in the presence of a catalytic amount of molecular iodine at 160 °C, under neat conditions (**Scheme 2**).⁴⁴ The same reaction conditions were implemented to prepare of 2,2,4-trimethyl-1,2-dihydroquinoline derivatives (**5** and **6**) by reacting the corresponding aniline derivative with acetone through a Skraup-Doebner-Von-Miller quinoline synthesis mechanism (**Scheme 3**).^{43,45} Under identical conditions but using cyclopentanone instead of acetone (**Scheme 4**), compound **7** was produced.⁴⁵ On the other hand, reacting a 2,2,4-trimethyl-1,2-dihydroquinoline with either cyclohexanone or cyclopentanone produced compounds **8** and **9**, respectively, as illustrated in Scheme 5.^{44,45}

Scheme 2: Synthesis of 4-cyclohexenylaniline derivatives⁴⁴

Scheme 3: Synthesis of 2,2,4-trimethyl-1,2-dihydroquinoline derivatives^{43,45}

Scheme 4: Reaction of 4-ethoxyaniline derivatives with cyclopentanone⁴⁵

Scheme 5: Reaction of 2,2,4-trimethyl-1,2-dihydroquinoline derivative with cyclohexanone or cyclopentanone^{44,45}

C–N linked biphenyls were prepared by dimerizing the corresponding aniline derivative via a silver(I) catalyzed direct C–H functionalization, as illustrated in **Scheme 5**.⁴⁶ As for 2'-aminobiphenyl-2-ols, the largest family of compounds screened during this study, they were also prepared using silver(I) as a catalyst under reaction conditions very similar to those used in the preparation of C–N linked biphenyls. In this latter case, the aniline derivative was cross-coupled with the appropriate phenol via a regioselective aerobic oxidative cross-coupling, resulting also in a direct C–H functionalization.⁴⁷ However, sodium persulfate ($\text{Na}_2\text{S}_2\text{O}_8$) used as the oxidizing agent in C–N coupling reactions was replaced in this case by hydrogen peroxide (H_2O_2), resulting in a C–C coupling.⁴⁷

Scheme 5: Synthesis of C–N linked biphenyls⁴⁶

As such, 2-naphthol was reacted with a number of aniline derivatives (Scheme 6), and by varying the substituents either on the phenol or aniline starting materials, a number of 2'-aminobiphenyl-2-ol derivatives were prepared, as shown in **Figure 1**. The structure of compounds **12**, **13** and **16** was unambiguously confirmed by single crystal X-ray diffraction, and the molecular structures with thermal ellipsoid representation at 50% probability are provided.

Scheme 6: Synthesis of 1-(2-aminophenyl)naphthalen-2-ol derivatives. The single crystal X-ray data for **12** (CCDC 821630)⁴⁸ and **13** (CCDC 1442427)⁴⁷ are deposited in the Cambridge database, and copies of these materials can be obtained free of charge from CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, <http://www.ccdc.am.ac.uk>.

Figure 1: List of other 2'-aminobiphenyl-2-ol derivatives screened in this study. The single crystal X-ray data for **16** (CCDC 1442428)⁴⁷ are deposited in the Cambridge database, and copies of these materials can be obtained free of charge from CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, <http://www.ccdc.am.ac.uk>.

2.2. In vitro anticancer screening

The growth-suppressive and cytotoxic activities of a small library of about 90 compounds containing the above-described molecules were then screened against many of skin cancer cell lines including melanoma (A375 and SKMEL-28) and non-melanoma (A431 and SCC-12), with HaCaT keratinocytes used as a control,

using *in vitro* MTT and trypan blue dye exclusion assays. The activity was assessed as previously reported,^{25,41} and based in each case on the concentration of the sample capable of reducing the measured viability of the cell population to 50% of the maximum for each of the cell lines, and thus is expressed as IC₅₀. Hit compounds are identified as any molecule displaying a low micromolar activity against any of the cell lines used in the assay.

Many of the hit compounds appear to be primarily active against the non-melanoma A431 and SCC-12 cell lines at the micromolar range, and only a handful of them display any activity against the melanoma A375 and SKMEL-28 cell lines, as summarized in **Table 1**.

Table 1: Cytotoxicity (IC₅₀; μ M) values of the hit compounds against four human skin cancer cell lines; melanoma (A375 and SKMEL-28) and non-melanoma (A431 and SCC-12) cells, with HaCaT keratinocytes as a control

	Non-melanoma cell lines		Melanoma cell lines		Normal cell line
Compounds	A431 (IC ₅₀ μ M) ^a	SCC-12 (IC ₅₀ μ M) ^a	SKMEL-28 (IC ₅₀ μ M) ^a	A375 (IC ₅₀ μ M) ^a	HaCaT (IC ₅₀ μ M) ^a
1	8.60±0.55	35.5±1.81	>40.0	>40.0	28.7±1.00
2	4.70±0.78	35.9±0.85	>40.0	>40.0	33.9±2.08
3	12.8±1.69	31.9±3.31	>40.0	>40.0	37.1±3.00
4	20.6±0.74	33.3±0.68	>40.0	>40.0	>40.0
5	10.4±1.34	27.9±1.30	12.2±2.44	>40.0	>40.0
6	10.1±1.89	>40.0	36.4±1.22	>40.0	>40.0
7	10.0±0.91	24.6±3.71	17.1±0.38	>40.0	28.8±0.37
8	14.8±0.73	>40.0	>40.0	>40.0	33.0±2.42
9	15.2±3.50	34.7±0.88	>40.0	>40.0	>40.0
10	5.10±1.06	31.9±3.31	>40.0	>40.0	25.0±1.52
11	5.00±0.80	2.90±0.58	4.90±0.55	6.70±0.47	6.60±1.45
12	10.0±0.76	12.9±1.50	29.9±1.10	>40.0	35.4±1.68
13	5.00±0.94	3.30±0.58	13.8±0.88	17.1±0.94	11.2±0.27
14	17.1±1.02	16.3±0.28	>40.0	>40.0	>40.0
15	8.00±1.24	13.3±0.27	24.8±1.25	>40.0	27.3±1.32
16	14.0±0.71	32.8±1.78	>40.0	>40.0	>40.0
17	6.60±0.56	23.5±1.76	>40.0	>40.0	>40.0
18	17.5±2.14	>40.0	>40.0	>40.0	>40.0
19	8.00±2.95	18.6±1.15	>40.0	>40.0	31.1±1.58
20	17.1±2.40	25.3±1.45	>40.0	>40.0	>40.0

21	15.3±6.12	>40.0	>40.0	>40.0	>40.0
22	32.8±1.55	16.5±0.52	31.1±0.90	>40.0	>40.0
23	16.9±2.21	>40.0	32.2±1.44	>40.0	>40.0
24	16.2±1.15	18.3±1.07	39.1±1.02	>40.0	>40.0
25	28.6±5.04	17.1±1.59	17.5±1.83	>40.0	35.1±2.25
26	22.8±2.14	33.7±1.45	>40.0	>40.0	>40.0
27	24.0±3.45	18.0±1.41	38.6±1.53	>40.0	>40.0
28	30.2±2.83	22.4±1.49	28.6±2.84	>40.0	>40.0
29	33.5±0.11	32.2±2.93	>40.0	>40.0	>40.0
30	20.9±2.18	30.0±0.79	>40.0	>40.0	>40.0
31	23.5±3.81	31.8±1.97	>40.0	>40.0	>40.0
32	38.8±2.15	26.2±1.26	>40.0	>40.0	>40.0
33	12.6±0.71	38.9±0.09	>40.0	>40.0	>40.0
34	21.4±1.48	28.4±1.79	>40.0	>40.0	>40.0
35	22.6±1.99	28.7±0.21	>40.0	>40.0	>40.0
^b Cisplatin	7.7±0.34	4.4±0.24	14.21±0.24	1.49±0.44	3.4±0.42

^a Data are expressed as the mean ± SD from the dose-response curves of at least six independent experiments performed in sextuplicates; the incubation time for each compound with cells was 48 h; the cytotoxicity was measured by MTT assay; IC₅₀: compound concentration required to inhibit tumor cell proliferation (assessed as cell viability) by 50%. ^b Cisplatin (a well-known anticancer agent) was used as a positive control. Graphpad Prism software was used for statistical analyses.

In fact, the two methylgallate derivatives **1** (IC₅₀ 8.60 μM) and **2** (IC₅₀ 4.70 μM) and the aniline derivative **10** (IC₅₀ 5.10 μM) displayed a low micromolar activity against the A431 cell line, while the other aniline derivatives **3** and **4** were not as active. However, these simple benzene derivatives are all inactive against the other cancer cell lines used in this study. Nevertheless, the dimerization of **10** resulted in compound **11** (A431: IC₅₀ = 5.00 μM, SCC-12: IC₅₀ = 2.90 μM, SKMEL-28: IC₅₀ = 4.90 μM, A375: IC₅₀ = 6.70 μM), the most potent of the series across all the four cell lines. While **11** is the most active against all cell lines used in this study, especially in SCC-12 (a non-melanoma cell line) and SKMEL-28 (a melanoma cell line), it exhibited a low selectivity although comparable to that of the control drug cisplatin.

The 1,2-dihydroquinoline derivatives **5** (A431: IC₅₀ = 10.4 μM, SKMEL-28: IC₅₀ = 12.2 μM), **6** (A431: IC₅₀ = 10.1 μM, SKMEL-28: IC₅₀ = 36.4 μM) and **7** (A431: IC₅₀ = 10.0 μM, SKMEL-28: IC₅₀ = 17.1 μM) displayed comparable levels of activity against the non-melanoma cell A431, but were more active against the melanoma cell line SKMEL-28 than they were against SCC-12 (the other non-melanoma cell line), while

completely inactive against A375. They also displayed a better selectivity index than the simple benzene derivatives. As for the C–C-linked biphenyl group **12** – **35**, many of them displayed some activity against A431, including **12** (A431: IC₅₀ = 10.0 µM), **15** (A431: IC₅₀ = 8.00 µM), **17** (A431: IC₅₀ = 6.60 µM), **19** (A431: IC₅₀ = 8.00 µM), and **33** (A431: IC₅₀ = 12.60 µM), while being only marginally active or completely inactive against the other cell lines, including SCC-12. Compound **13** (A431: IC₅₀ = 5.00 µM, SCC-12: IC₅₀ = 3.30 µM, SKMEL-28: IC₅₀ = 13.8 µM, A375: IC₅₀ = 17.1 µM) was the most active of the group across all the cell lines, with a better selectivity index than **11** or cisplatin. The diversity of substituents on the biphenyl rings appears to be very limited, and as such, no evident electronic or steric trend could be observed. For example, the only difference between **12** and **13** is that the para-methyl group on the aniline derivative in **12** is replaced at the same position by an ethoxy group in **13**; although both groups are electron-donating in nature, these two compounds displayed a wide difference in activity. Surprisingly, compound **14**, carrying an ethoxy group at the same position as **13**, but a benzyl rather than a methyl group on the nitrogen atom, displayed a similar activity as **12** that carries a methyl group at both positions. Furthermore, the presence of 4-Br (**18**), 4-Cl (**19**), 4-OMe (**20**), 4-Me (**21**), 4-iPr (**22**), 3,4-diCl (**24**), or 3,4-diMe (**25**) on the phenol ring did not have a significant impact on the activity of these compounds as compared to **17**, which carries no substituent on the phenol ring. The variation of the substituents on the nitrogen of the aniline also does not appear to significantly impact on the activity of the resulting compounds, although some differences in activity were observed, primarily with the A431 cell line. As such, it is still unclear why compounds **11** and **13** appear to have significantly greater activity than the remaining hit compounds across the four cell lines used in the study. Furthermore, cisplatin, a well-known anticancer agent used as a positive control, appeared to be less cytotoxic than some of the hit compounds towards these cancer cell lines and displayed a much lower selectivity index than many of these small molecules, as indicated by its activity against mammalian nontumorigenic immortalized HaCaT cells. In

fact, some compounds such as **2** (A431: IC₅₀ = 4.70 µM, HaCaT: IC₅₀ = 33.9 µM), **10** (A431: IC₅₀ = 5.00 µM, HaCaT: IC₅₀ = 25.0 µM), or **19** (A431: IC₅₀ = 8.00 µM, HaCaT: IC₅₀ = 31.1 µM) for example, exhibited a similar or better activity than cisplatin against A431 cell line, and almost not toxicity against HaCaT, even if the activity was not maintained across all cell lines. This is a good indication that the activity and selectivity of this family of compounds can be improved by designing and preparing more appropriate analogs. As such, further study with more diversely substituted biphenyl analogs is needed to be able to develop a more complete structure-activity profile, and in the process hopefully improve their anticancer activity. More importantly, since these compounds bear some similarity to ellagic acid, a well-established anticancer molecule,⁴⁹⁻⁵² further studies on the way in our lab will establish whether the planarity of ellagic acid or the atropisomerism of the hit compounds described in this report have any effects on the anticancer property of the respective molecules. The culmination will be a better understanding of the anticancer profile of the biphenyl family of compounds. Towards this objective, a preliminary target validation was undertaken using a combination of molecular docking and ADMET, western blotting, scratch wound healing, apoptosis, and colony formation assays. Beyond the scope of the current report, further investigations of target proteins are underway in our laboratory.

2.3. *In silico target(s) prediction, pharmacokinetic and ADMET studies*

Bio- and chemo-informatics approaches have progressively established themselves as important tools to estimate the most probable targets of small molecules.⁵³⁻⁵⁵ As such, computer-aided ligand-based target prediction techniques, also known as “target fishing,” have proven to be fast and exceedingly accurate in predicting the correct protein target(s) in drug discovery.^{56,57} SwissTargetPrediction, the tool used in this study, quantifies similarities between compounds by computing a pair-wise comparison of 1D vectors describing molecular structures,⁵⁸ determines the Tanimoto index between path-based binary fingerprints (FP2) through 2D measurements,⁵⁸ and evaluates the Manhattan distance similarity between

Electroshape 5D (ES5D) float vectors through a 3D assessment,⁵⁸⁻⁶⁰ to intuitively validate the “molecular similarity hypothesis,” based on the credence that similar molecules target common proteins.⁵⁸⁻⁶¹ Based on these parameters, a “CombinedScore” of 0.5 or higher is an indication that the molecules are likely to share a common protein target.⁵⁸ It should be clarified that these data are only suggestive of the probability for a molecule to interact with a given protein as a target, and not an indication of the compound being bioactive. Nevertheless, SwissTargetPrediction has documented and stored about 2,579 protein targets, 1,768 of which are human’s, 280,381 active compounds and more than 440,534 interactions.⁵⁸

As such, in order to gain more insights into the behavioral profile of the hit compounds identified through whole-cell *in vitro* assays, their binding efficiency was compared *in silico*, to that of a natural and a commercial ligand, through a reverse screening study. These compounds appear to have a favorable binding affinity with only a selected number of enzymes, phosphodiesterases, kinases, proteases, oxidoreductases, erasers, and ligand-gated ion channels, as summarized in **Table 2 and 3**. Compounds **1 – 4** and **10 – 11**, which are primarily substituted benzene derivatives, displayed considerable interactions only with two kinases (RAF1 and dual-specificity protein kinase CLK4), one protease (MMP9), one oxidoreductase (monoamine oxidase B), and one eraser (deacetylase NAD-dependent Sirtuin 2). They also showed some strong binding with the cannabinoid receptor 2, and with the nuclear receptor ROR-gamma. Compounds **5 – 9**, which are dihydroquinoline derivatives, were less selective, exhibiting a strong binding with six enzymes (anandamide amidohydrolase, arachidonate 5 lipoxygenase, arachidonate 15 lipoxygenase, nicotinamide phosphoribosyltransferase, PARP and PI3-kinase p110-alpha subunit), three phosphodiesterases (4B, 5A and 10A), eight kinases (RAF1, ROCK1, ROCK2, serine-threonine protein kinase Chk1, tyrosine-protein kinase FYN, tyrosine protein kinase LCK, CDK8, and dual specificity protein kinase CLK4), one protease (MMP9), two oxidoreductase (COX-2 and monoamine oxidase B), and one

eraser (deacetylase NAD dependent Sirtuin 2). These compounds (**5 – 9**) also displayed good interaction with other potential targets including the cholesterol ester transfer protein, the cannabinoid receptor 2, a primary active transporter (P-glycoprotein 1), and several of nuclear proteins and receptors (peroxisome-proliferator activated receptor-gamma, orphan nuclear receptor LRH-1, nuclear receptor ROR-gamma, and MDM2).

The most prominent family of compounds among the identified hits, made of C – C-linked biphenyls (**12 – 35**), displayed interaction with almost the same array of potential targets as dihydroquinoline derivatives. They showed similar interaction with six enzymes (anandamide amidohydrolase, arachidonate 5 lipoxygenase, arachidonate 15 lipoxygenase, nicotinamide phosphoribosyltransferase, PARP and PI3-kinase p110-alpha subunit), three phosphodiesterases (4B, 5A and 10A), eight kinases (RAF1, ROCK1, ROCK2, serine-threonine protein kinase Chk1, tyrosine-protein kinase FYN, tyrosine protein kinase LCK, CDK8, and dual-specificity protein kinase CLK4), one protease (MMP9), two oxidoreductases (COX-2 and monoamine oxidase B), and one eraser (deacetylase NAD dependent Sirtuin 2). Like dihydroquinoline derivatives, compounds (**12 – 35**) consistently showed a favorable binding coefficient with the nuclear receptor ROR-gamma. These compounds also exhibited some interactions with the cholesterol ester transfer protein, the cannabinoid receptor 2, a primary active transporter (P-glycoprotein 1), the orphan nuclear receptor LRH-1, and the nuclear receptor ROR-gamma. However, unlike the dihydroquinoline derivatives, they showed no interactions with the peroxisome-proliferator activated receptor-gamma or with MDM2. It should be mentioned that many of these enzymes, kinases, proteases, transporters, and receptors have been shown to play essential roles in skin carcinogenesis, and cancer progression. A decrease in anandamide signaling was shown as a potential contributor to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain.⁶²⁻⁶⁴ Taken together with the fact that pharmacological activation of cannabinoid receptors appeared to induce the apoptotic

death of tumorigenic epidermal cells without affecting the viability of non-transformed epidermal cells,⁶⁵
these studies suggest that the manipulation of peripheral endocannabinoid signaling can be a promising
strategy for the management of some types of cancers.

Table 2: Binding affinity of the hit compounds toward enzymes and phosphodiesterases as compared to natural and commercial ligands

Ligands	Enzymes						Phosphodiesterases		
	Anandamide amidohydrolase	Arachidonate 5 lipoxygenase	Arachidonate 15 lipoxygenase	Nicotinamide phosphoribosyltra nsferase	PARP	PI3-kinase p110-alpha subunit	Phosphodi esterase 4B	Phosphodi esterase 5A	Phosphodi esterase 10A
Natural	- 8.6	- 6.6	- 5.3	- 11.9	- 11.1	- 9.1	- 9.1	- 10.7	- 10.5
CL	MK4409 - 8.1	α -boswellic acid - 8.5	Hydroxyoctade cadiomic acid - 7.3	Daporinad - 9.7	Olaparib - 11.1	Copanlisib - 8.3	Apremilast - 7.7	Sildenafil - 8.8	pubchem 629793 - 8.2
1	- 5.9	- 4.6	- 5.1	- 5.6	- 5.2	- 5.2	- 6.1	- 5.8	- 5.0
2	- 6.3	- 4.7	- 5.1	- 6.1	- 6.8	- 5.4	- 6.2	- 5.7	- 5.9
3	- 7.7	- 6.8	- 6.8	- 7.8	- 7.9	- 7.9	- 7.2	- 7.3	- 7.4
4	- 8.3	- 6.9	- 7.6	- 7.9	- 7.8	- 7.7	- 7.8	- 7.2	- 7.4
5	- 7.9	- 6.2	- 6.8	- 7.5	- 7.7	- 6.5	- 6.9	- 7.4	- 7.5
6	- 7.6	- 6.1	- 6.5	- 7.2	- 7.4	- 6.3	- 7.0	- 7.3	- 7.3
7	- 10.3	- 8.2	- 8.7	- 9.8	- 7.8	- 8.0	- 9.2	- 9.8	- 9.3
8	- 9.6	- 8.0	- 8.4	- 9.1	- 7.7	- 7.6	- 8.3	- 9.4	- 7.7
9	- 9.1	- 8.6	- 9.1	- 10.5	- 9.6	- 9.0	- 9.3	- 10.7	- 8.7
10	- 5.7	- 4.7	- 5.6	- 5.6	- 5.8	- 5.5	- 5.5	- 5.3	- 5.5
11	- 7.5	- 6.0	- 6.9	- 7.5	- 7.8	- 6.5	- 6.5	- 7.2	- 6.3
12	- 7.8	- 8.0	- 7.3	- 7.7	- 7.8	- 6.9	- 7.6	- 7.3	- 8.0
13	- 8.2	- 6.1	- 7.4	- 7.7	- 8.3	- 6.5	- 7.8	- 7.2	- 7.4

14	- 8.4	- 7.7	- 8.0	- 8.9	- 7.2	- 7.2	- 8.4	- 8.3	- 7.8
15	- 7.8	- 7.6	- 7.6	- 8.2	- 8.4	- 6.6	- 7.0	- 7.6	- 7.6
16	- 8.3	- 8.0	- 8.2	- 8.6	- 9.0	- 9.3	- 8.0	- 8.2	- 8.5
17	- 7.3	- 6.2	- 6.8	- 7.2	- 6.6	- 7.0	- 6.5	- 8.1	- 6.7
18	- 7.0	- 6.4	- 6.4	- 7.0	- 6.7	- 6.3	- 6.8	- 7.7	- 6.4
19	- 7.4	- 6.3	- 6.6	- 6.9	- 6.8	- 6.2	- 6.8	- 7.6	- 6.4
20	- 7.8	- 6.0	- 6.4	- 6.9	- 6.7	- 6.2	- 6.8	- 8.1	- 7.1
21	- 7.4	- 6.5	- 6.7	- 7.1	- 7.0	- 6.4	- 6.9	- 7.8	- 6.5
22	- 8.1	- 7.0	- 6.9	- 7.4	- 7.2	- 8.0	- 7.1	- 7.2	- 7.1
23	- 7.9	- 6.5	- 6.7	- 7.0	- 6.8	- 6.4	- 6.6	- 7.8	- 6.9
24	- 7.3	- 6.4	- 6.9	- 7.1	- 6.9	- 5.7	- 6.3	- 6.3	- 6.4
25	- 7.6	- 6.8	- 7.0	- 7.2	- 7.1	- 6.5	- 6.6	- 7.1	- 6.7
26	- 7.3	- 6.1	- 6.7	- 7.0	- 7.1	- 6.3	- 6.4	- 8.0	- 6.2
27	- 8.0	- 6.0	- 6.7	- 7.1	- 7.2	- 6.7	- 6.7	- 7.5	- 6.1
28	- 7.7	- 6.3	- 7.3	- 7.2	- 6.9	- 6.5	- 6.6	- 7.8	- 6.5
29	- 8.4	- 6.5	- 6.9	- 7.3	- 7.0	- 6.9	- 6.7	- 7.9	- 6.6
30	- 8.2	- 6.3	- 6.7	- 7.7	- 7.4	- 6.6	- 7.0	- 8.0	- 6.4
31	- 8.0	- 6.7	- 7.8	- 8.2	- 7.2	- 7.0	- 7.5	- 7.1	- 7.0
32	- 7.6	- 7.0	- 7.5	- 8.2	- 6.8	- 7.9	- 7.1	- 7.5	- 7.4
33	- 7.0	- 6.1	- 6.7	- 7.1	- 7.2	- 6.3	- 6.4	- 7.9	- 6.3
34	- 7.8	- 6.2	- 6.5	- 7.2	- 7.3	- 6.5	- 6.6	- 7.5	- 6.5
35	- 7.6	- 6.3	- 6.4	- 7.2	- 7.2	- 6.4	- 6.8	- 7.7	- 6.1

Table 3: Binding affinity of the hit compounds toward kinases, proteases, oxidoreductases and erasers as compared to natural and commercial ligands

Ligands	Kinases								Protease	Oxidoreductase		Eraser
	RAF1	ROCK1	ROCK2	Serine-threonine protein kinase Chk1	Tyrosine protein kinase FYN	Tyrosine protein kinase LCK	CDK8	Dual Specificity protein kinase CLK4	MMP9	COX-2	Monoamine oxidase B	deacetylase NAD dependent Sirtuin 2
Natural	- 10.2	- 8.2	- 10.7	- 10.1	- 11.2	- 12.8	- 8.2	- 10.3	- 11.4	- 10.3	- 6.9	- 12.9
CL	Sorafinib - 10.6	Y27632 - 7.2	fasudil - 8.3	Rabusertib - 8.4	Saracatinib - 8.9	Masitinib - 9.0	Cortistatin - A - 9.9	CID 46926514 - 10.6	Apigenin - 10.2	Celecoxib - 10.8	Benmoxin - 8.9	3'-Phenethyl Oxy benzamide - 13.2
1	- 4.6	- 4.8	- 5.9	- 5.7	- 5.8	- 4.8	- 6.3	- 6.2	- 6.2	- 6.1	- 5.6	- 5.5
2	- 5.8	- 5.9	- 6.0	- 5.6	- 6.1	- 5.5	- 6.1	- 6.2	- 6.3	- 6.2	- 6.2	- 6.3
3	- 8.4	- 6.9	- 7.3	- 7.2	- 7.3	- 8.0	- 7.0	- 8.2	- 9.1	- 7.4	- 8.2	- 10.1
4	- 8.1	- 6.7	- 7.3	- 7.4	- 7.6	- 7.9	- 7.5	- 8.4	- 9.1	- 7.6	- 8.2	- 10.6
5	- 6.4	- 7.2	- 7.2	- 7.2	- 7.2	- 6.9	- 7.6	- 9.2	- 7.6	- 7.5	- 8.2	- 8.1
6	- 6.4	- 6.7	- 7.4	- 6.9	- 7.0	- 6.7	- 7.4	- 9.1	- 7.0	- 7.2	- 7.7	- 8.1
7	- 8.4	- 7.2	- 9.0	- 10.0	- 10.0	- 8.6	- 9.5	- 10.4	- 8.3	- 9.8	- 9.2	- 5.8
8	- 7.4	- 7.8	- 9.0	- 8.3	- 9.4	- 8.3	- 8.8	- 10.6	- 8.2	- 9.4	- 8.6	- 8.5
9	- 9.1	- 8.4	- 9.4	- 9.8	- 9.4	- 9.8	- 9.1	- 10.9	- 9.5	- 9.7	- 10.3	- 9.5
10	- 5.7	- 5.3	- 5.5	- 5.4	- 5.1	- 5.3	- 5.4	- 6.2	- 6.4	- 5.9	- 5.9	- 7.0
11	- 6.8	- 6.5	- 7.0	- 7.0	- 6.8	- 6.7	- 7.2	- 7.0	- 7.7	- 7.6	- 7.7	- 5.2
12	- 5.7	- 7.2	- 8.2	- 8.0	- 8.5	- 8.9	- 8.4	- 8.2	- 8.4	- 8.3	- 8.6	- 8.1
13	- 5.9	- 7.1	- 8.6	- 8.0	- 8.3	- 8.8	- 8.2	- 8.8	- 8.0	- 8.4	- 8.4	- 8.4

14	- 5.9	- 7.8	- 9.7	- 8.1	- 7.5	- 8.0	- 7.1	- 9.7	- 8.3	- 9.3	- 8.5	- 4.5
15	- 5.8	- 7.3	- 8.7	- 7.6	- 7.7	- 8.1	- 8.7	- 8.9	- 8.0	- 8.6	- 8.3	- 7.2
16	- 8.6	- 8.0	- 8.3	- 9.4	- 9.1	- 10.0	- 8.4	- 9.1	- 9.1	- 9.3	- 9.4	- 10.3
17	- 6.6	- 6.3	- 6.7	- 7.0	- 7.2	- 7.8	- 7.1	- 7.7	- 7.6	- 8.0	- 8.1	- 8.1
18	- 7.0	- 6.5	- 7.2	- 7.3	- 7.3	- 8.0	- 7.1	- 7.4	- 7.6	- 7.9	- 8.6	- 7.9
19	- 7.0	- 6.7	- 7.1	- 7.4	- 7.4	- 8.0	- 7.0	- 7.4	- 7.8	- 7.9	- 8.5	- 8.5
20	- 6.9	- 6.9	- 7.0	- 6.9	- 7.2	- 7.8	- 7.2	- 7.4	- 7.9	- 7.8	- 8.3	- 8.0
21	- 7.3	- 6.9	- 7.2	- 7.5	- 7.7	- 8.2	- 7.2	- 7.6	- 7.9	- 8.1	- 8.6	- 8.8
22	- 6.5	- 7.0	- 7.0	- 8.1	- 7.5	- 8.0	- 7.9	- 7.7	- 8.4	- 8.1	- 9.0	- 8.6
23	- 6.4	- 6.5	- 7.0	- 7.2	- 6.9	- 8.0	- 7.3	- 8.1	- 7.5	- 8.0	- 8.5	- 8.7
24	- 6.5	- 6.3	- 7.3	- 6.8	- 6.9	- 7.0	- 7.3	- 7.5	- 6.6	- 7.3	- 7.5	- 6.8
25	- 6.7	- 6.4	- 7.6	- 7.3	- 6.9	- 8.1	- 7.3	- 7.8	- 6.8	- 7.5	- 7.8	- 7.4
26	- 6.5	- 6.1	- 6.8	- 6.8	- 7.6	- 6.7	- 7.1	- 7.4	- 7.3	- 8.1	- 7.6	- 7.5
27	- 7.2	- 6.3	- 7.3	- 7.2	- 7.6	- 7.0	- 7.0	- 8.2	- 7.3	- 7.9	- 8.3	- 7.4
28	- 7.0	- 6.6	- 7.2	- 6.9	- 7.4	- 7.4	- 7.1	- 8.3	- 7.5	- 8.1	- 7.7	- 8.2
29	- 7.3	- 6.3	- 7.7	- 7.0	- 8.3	- 7.1	- 7.4	- 7.6	- 7.6	- 7.9	- 8.0	- 5.7
30	- 5.5	- 6.6	- 7.8	- 6.5	- 8.4	- 6.3	- 7.2	- 7.5	- 7.7	- 8.0	- 8.1	- 7.9
31	- 7.1	- 6.1	- 7.7	- 8.3	- 8.7	- 7.3	- 8.3	- 8.5	- 8.3	- 8.9	- 8.8	- 9.0
32	- 7.9	- 7.4	- 8.4	- 7.8	- 8.5	- 7.6	- 8.3	- 8.5	- 8.3	- 8.6	- 8.7	- 5.8
33	- 6.4	- 6.2	- 6.5	- 6.7	- 7.2	- 6.8	- 6.9	- 7.4	- 7.1	- 7.9	- 8.0	- 6.2
34	- 5.2	- 6.2	- 7.0	- 7.2	- 7.2	- 6.0	- 7.1	- 7.0	- 7.2	- 7.5	- 7.8	- 6.7
35	- 7.9	- 7.4	- 8.4	- 7.8	- 8.5	- 7.6	- 8.3	- 8.5	- 8.3	- 8.6	- 8.7	- 5.8

Moreover, lipoxygenases are well known to catalyze the formation of corresponding hydroperoxides from polyunsaturated fatty acids such as linoleic acid and arachidonic acid, and they are expressed in immune, epithelial, and tumor cells associated with other physiological conditions, such as skin inflammation, and tumorigenesis.^{66,67} Many kinases, including RAF1,^{68,69} ROCK1 and 2,^{70,71} serine-threonine protein kinase (CHK1),^{72,73} tyrosine-protein kinase (FYN),^{74,75} tyrosine protein kinase (LCK),⁷⁶ and dual specificity protein kinase (CLK4) are also well known to play critical roles in skin tumorigenesis as well as in other cancer types. In fact, SKMEL-28 (one of a series of melanoma cell lines established from patient-derived tumor samples) and A375, both used in this study, are well-known to harbor BRAF V600E driver mutation and wildtype N-RAS.⁷⁷ On the other hand, nicotinamide adenine dinucleotide (NAD)-biosynthetic enzyme (nicotinamide phosphoribosyltransferase also known as NAMPT) was shown to be a driving factor in resistance associated with serine-threonine protein kinase B-RAF (BRAF)-mutated metastatic melanoma, one of the highly aggressive types of skin cancer.^{78,79}

Further studies revealed that NAMPT over-expression is necessary and sufficient to recapitulate the BRAFi-resistant phenotype plasticity.⁷⁸ It should also be mentioned that PI3K/RAC alpha serine/threonine protein kinase (AKT)/mTOR signaling pathway has been shown to be over-activated in some types of skin cancers,⁸⁰ with the anti-proliferative activity of some phenolic compounds against SK-MEL-2 cancer cells attributed to the downregulation of the PI3K/AKT/mTOR signaling pathway, which induces a mitochondrial-dependent apoptosis.⁸¹

Other potential targets revealed during the *in silico* “target fishing” reverse screening, including Poly(ADP-ribose)polymerase (PARP),^{82,83} phosphodiesterase type 5,^{84,85} orphan nuclear receptor LRH-1,^{86,87} nuclear receptor ROR-gamma,^{88,89} matrix metalloproteinase 9 (MMP9),⁹⁰ NAD-dependent deacetylase Sirtuin 2,⁹¹ and cholesterol ester transfer protein,⁹² all believed to play important roles in skin carcinogenesis. There is no doubt that the wealth of information gathered here will be useful in further studies towards the

optimizing the hit molecules' activity and determining their putative drug target and potential mechanism(s) of action.

Finally, the drug-likeness properties of these compounds were evaluated *in silico*, using the SwissADME web tool.^{58,93} **Table 4** displays some physicochemical properties, ADME parameters, and violations of drug-likeness rules for these compounds. These properties were computed exploiting various filters widely used to evaluate the drug-likeness of a wide range of compounds. This includes the Lipinski (Pfizer) filter ($MW \leq 500$; $MLOGP \leq 4.15$; $HBA \leq 10$; $HBD \leq 5$),⁹⁴ the Ghose filter ($160 \leq MW \leq 480$; $-0.4 \leq WLOGP \leq 5.6$; $40 \leq MR \leq 130$; $20 \leq \text{atoms} \leq 70$),⁹⁵ Veber (GSK) filter ($RB \leq 10$; $TPSA \leq 140$),⁹⁶ Egan (Pharmacia) filter ($WLOGP \leq 5.88$; $TPSA \leq 131.6$),⁹⁷ and Muegge (Bayer) filter ($200 \leq MW \leq 600$; $-2 \leq XLOGP \leq 5$; $TPSA \leq 157$; $HBA \leq 10$; $HBD \leq 5$; $RB \leq 15$; number of rings ≤ 7 ; number of carbons > 4 ; number of heteroatoms > 1).⁹⁸

The obtained results indicate that the drug-likeness of all these hit compounds are well within the defined parameters for a good drug candidate. More importantly, the bioavailability score of about 0.55 obtained for all these compounds satisfies Lipinski's rule for a neutral compound for an optimal absorption through oral ingestion,⁹⁴ suggesting that these compounds could be good oral drug candidates, in case they were to display useable anticancer properties. The synthetic accessibility scores for these compounds were also very low, indicating ease to readily prepare derivatives for further structure-activity relationship studies. Furthermore, as indicated in the chemistry section, all these compounds were synthesized by our research group through simple and straightforward methods that can be easily adapted for the preparation of the more potent analogs.

Table 4: Physicochemical and pharmacokinetic properties of the hit compounds

Comp.	MW (g/mol)	Lipophilicity						Drug-likeness (number of violations)					Water Solubility		Pharmacokinetics	
		ilogP	XlogP3	WlogP	MlogP	Silicos- IT logP	Consensus logP	Lipinski	Ghose	Veber	Egan	Muegge	ESOL	Class	Log K_p (cm/s)	F
1	384.018	3.18	3.07	3.02	2.17	3.23	2.93	0	0	0	0	0	-4.07	moderately	-6.46	0.55
2	271.223	2.23	1.52	1.41	-0.11	-0.26	0.96	0	0	0	0	0	-2.32	easily	-6.88	0.55
3	201.307	3.00	4.65	3.71	3.38	3.23	3.60	0	0	0	0	1	-4.18	moderately	-4.23	0.55
4	235.752	3.21	4.62	4.54	3.91	4.29	4.11	0	0	0	0	1	-4.29	moderately	-4.46	0.55
5	217.307	3.01	3.11	3.12	2.73	3.32	3.06	0	0	0	0	0	-3.29	easily	-5.42	0.55
6	203.280	2.72	2.74	2.73	2.46	2.96	2.72	0	0	0	0	0	-3.06	easily	-5.59	0.55
7	335.482	4.20	4.78	5.76	4.74	5.82	5.06	1	1	0	0	0	-4.91	moderately	-4.95	0.55
8	297.434	4.04	4.83	5.08	4.09	5.09	4.62	0	0	0	0	0	-4.73	moderately	-4.69	0.55
9	305.456	4.21	5.13	5.86	5.10	5.89	5.24	1	1	0	0	2	-5.03	moderately	-4.52	0.55
10	151.206	2.24	1.60	1.94	1.80	1.83	1.88	0	1	0	0	1	-1.99	very	-6.09	0.55
11	300.395	3.56	4.26	4.10	3.01	3.17	3.62	0	0	0	0	0	-4.33	moderately	-5.11	0.55
12	277.360	3.18	4.93	4.59	3.97	4.20	4.17	0	0	0	0	0	-5.10	moderately	-4.49	0.55
13	307.386	3.43	4.90	4.68	3.59	4.11	4.14	0	0	0	0	0	-5.08	moderately	-4.70	0.55
14	383.482	4.16	6.40	6.10	4.65	5.59	5.38	1	1	0	1	1	-6.41	poorly	-4.10	0.55
15	347.450	4.14	5.78	5.62	4.17	5.11	4.96	1	1	0	0	1	-5.69	moderately	-4.32	0.55
16	277.360	3.27	4.93	4.59	3.97	4.20	4.19	0	0	0	0	0	-5.10	moderately	-4.49	0.55
17	257.328	3.17	3.65	3.52	2.84	3.03	3.24	0	0	0	0	0	-3.94	easily	-5.28	0.55
18	336.224	3.62	4.34	4.29	3.47	3.70	3.88	0	0	0	0	0	-4.84	moderately	-5.27	0.55
19	291.773	3.51	4.28	4.18	3.35	3.66	3.88	0	0	0	0	0	-4.53	moderately	-5.04	0.55
20	287.354	3.68	3.63	3.53	2.50	3.08	3.28	0	0	0	0	0	-4.00	moderately	-5.48	0.55
21	271.354	3.35	4.02	3.83	3.09	3.54	3.57	0	0	0	0	0	-4.23	moderately	-5.10	0.55
22	299.407	3.70	4.78	4.65	3.56	4.15	4.17	0	0	0	0	0	-4.78	moderately	-4.73	0.55
23	291.773	3.53	4.28	4.18	3.35	3.66	3.80	0	0	0	0	0	-4.53	moderately	-5.04	0.55
24	326.218	3.30	4.77	4.83	3.86	4.31	4.21	0	0	0	0	0	-5.03	moderately	-4.90	0.55
25	285.381	3.43	4.38	4.14	3.32	4.06	3.87	0	0	0	0	0	-4.53	moderately	-4.93	0.55
26	285.381	3.75	4.55	4.30	3.32	3.80	3.95	0	0	0	0	0	-4.50	moderately	-4.81	0.55
27	364.277	3.41	5.24	5.07	3.94	4.48	4.43	0	0	0	0	1	-5.41	moderately	-4.80	0.55
28	299.407	3.56	4.98	4.55	3.56	4.02	4.13	0	0	0	0	0	-4.84	moderately	-4.59	0.55

29	378.303	4.16	5.68	5.31	4.16	4.70	4.80	0	0	0	0	1	-5.75	moderately	-4.57	0.55
30	364.277	3.84	5.14	5.07	3.94	4.31	4.46	0	0	0	0	1	-5.41	moderately	-4.87	0.55
31	333.424	3.70	5.15	4.94	3.99	4.54	4.46	0	0	0	0	1	-5.29	moderately	-4.68	0.55
32	412.320	3.92	5.84	5.70	4.58	5.22	5.05	1	1	0	0	1	-6.19	poorly	-4.67	0.55
33	299.407	3.99	4.91	4.69	3.56	4.19	4.27	0	0	0	0	0	-4.73	moderately	-4.64	0.55
34	378.303	4.08	5.61	5.46	4.16	4.87	4.84	0	0	0	0	1	-5.64	moderately	-4.62	0.55
35	364.277	3.75	5.08	5.07	3.94	4.48	4.46	0	0	0	0	1	-5.31	moderately	-4.92	0.55

Molecular weight (MW), LogP values (an indicator of lipophilicity), aqueous solubility parameters (ESOL), an indicator of skin permeation (Log K_p), and bioavailability score (F)

2.4. Preliminary investigation of the potential antiproliferative mechanism of action

In order to explore the potential antiproliferative mechanism of action of these molecules, the effects of the two most active compounds (**11** and **13**) on wound healing, colony formation and apoptosis-related properties were further investigated. A scratch wound assay was used to scrutinize the ability of these compounds to modulate the migration of SCC-12 and SKMEL-28 cells into cell-free areas produced by scratch-wounding after 48 h of incubation. Both compounds significantly decreased the scratched wound areas of cultured SCC-12 and SKMEL-28 cells after a 48 h treatment relative to the control untreated cells, in a dose-dependent manner, as illustrated in **Figure 2**. The long-term impacts of different concentrations (0, $\frac{1}{2}IC_{50}$, IC_{50} , and $1\frac{1}{2}IC_{50}$) of compounds **11** and **13** on colony formation potentials for SCC-12 and SKMEL-28 cells compared to controls were then explored. As depicted in **Figure 3A-B**, these compounds reduced the number of colonies formed in both SCC-12 and SKMEL-28 cells in a concentration-dependent manner. Further analysis revealed that these dose-dependent reductions in clonogenicity were significant in both cell lines, when compared to untreated control groups (**Figure 3C-F**).

Figure 2. The potent hit compounds **11** and **13**, dose-dependently (**0**, $\frac{1}{2}IC_{50}$, IC_{50} and $1\frac{1}{2}IC_{50}$; μM), inhibited the *in-vitro* migration of SCC-12 (**A**; top panel) and SKMEL-28 (**A**; bottom panel) cells into the cell-free wounded areas of a confluent cell monolayer scratched wound. Compounds **11** and **13** induced suppressions of wound closure of SCC-12 and SKMEL-28 cells were significant (**B**). Data show the evidential effect of test compounds in limiting the migration of cells in the inflicted *in-vitro* wounds healing. The bar graphs (**B**) represent the mean $\pm$ SD of scratched-wound area values after 48 h and are expressed as a percentage at 0 h untreated control from three independent experiments conducted in triplicates. Statistical significance was assessed using one-way ANOVA and Dunn's multiple comparison tests, $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***) and $p < 0.0001$ (****), were considered significant.

Figure 3. The potent phenolic compounds 11 and 13 significantly inhibit colony formation potentials in SCC-12 (A) and SKMEL-28 (B) cells cultured in monolayers after 14 days when control cells became confluent. The percentage decrease in colony formation was in a dose-dependent (0, $\frac{1}{2}IC_{50}$, IC_{50} and $1\frac{1}{2}IC_{50}$; μM), and were comparable in SCC-12 (C-D) and SK-MEL-28 (E-F) cells. The data expressed in the bar graphs represent the mean $\pm$ SD of colonies analyzed in compounds 11 and 13 treated groups expressed as a percentage of the untreated control group. Data are from three independent experiments,

each performed in quadruplicate. Statistical significance was assessed using one-way ANOVA and Dunn's multiple comparison tests, $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***) and $p < 0.0001$ (****), were considered significant.

Since **11** and **13** have proven to induce significant decreases in cell viability, it was worthwhile investigating the molecular mechanisms by which these compounds induce cytotoxicity by assessing their potential to modulate apoptosis in SCC-12 and SKMEL-28 cancer cell lines selectively. As such, the effects of the test compounds on cellular cytoskeleton (actin staining) and nuclear morphology (DAPI staining) **Figure 4A-B** (control; c and ca, and drug-treated; g-k and ga-ka), as well as on the activation of proapoptotic caspase-3 were assessed by comparing the apoptotic cells and caspase-3 cleavage to untreated groups via an immunofluorescent microscopy analysis. It was observed that the nuclei of SCC-12 and SKMEL-28 cells treated with compounds **11** and **13** exhibited the morphologies characteristic of fragmented chromatin with punctate apoptotic nuclei in a dose-dependent manner (data not shown). Compared to untreated SCC-12 cells (**Figure 4A(a)** and **4B(aa)**), which presented a well-organized actin filament cytoskeleton radiating across the cell cytoskeleton and extending to the lamellipodia, the drug-treated cells showed disoriented and diminished actin filament cytoskeleton. These effects were dose-dependent for both compound **11** (**Figure 4A(e-i)**, red) and compound **13** (**Figure 4B(ea-ia)**, red) in the SCC-12 cell line. As shown in **Figure 5**, similar potent effects were observed for **11** (**Figure 5A(e-i)**, red) and **13** (**Figure 5B(ea-ia)**, red) in the SK-MEL-28 cell line. With regards to the activation of proapoptotic caspase-3, untreated SCC-12 cells showed a regular staining pattern of procaspase-3 (**Figure 4A(b)** and **4B(ba)**, green). However, treatment with the indicated hit drugs dose-dependently activated caspase-3 and induced its translocation into the nucleus, as evidenced by the punctated active caspase-3 immunofluorescence staining detected in the nuclei as can be observed in cells treated with compounds **11** (**Figure 4A(f and j)**) and **13** (**Figure 4B(fa and ja)**), the punctated caspase-3 staining was colocalized with the nuclear actin staining, as illustrated in **Figure 4A (h and i)** for **11** and **Figure 4B (ha-ia)**, cyan) for **13**.

Compounds **11** (Figure 5A(f and j)) and **13** (Figure 5B(fa and ja)) also exhibited similar dose-dependent effects on the actin cytoskeleton as well as the caspase-3 activation status, which also served for the localization (cyan yellow) of the actin (red), nucleus (DAPI) and pro and active caspase-3 immunostaining (green) (see Figure 4 and 5).

Figure 4. Compounds **11** and **13** dose-dependently alter the actin cytoskeleton cell morphology and activate pro-apoptotic caspase-3 expression into the nucleus of the SCC-12 non-melanoma skin cancer cell line. Immunofluorescent micrographs analyses indicate that compounds **11** (A; e-l) and **13** (B; ea-la)

compared to untreated controls; for **11** (a-d) and for **13** (aa-da) morphologically distorted the actin cytoskeleton as well as decreased the actin expression levels (red) in monolayer cultures of SCC-12 in a dose-dependent (0, $\frac{1}{2}IC_{50}$, IC_{50} and $1\frac{1}{2}IC_{50}$; μM), as shown (red; a, e, i and aa, ae, ai). Similarly, the effect of **11**(A) and **13**(B) in activation (green; b,f,j and ba,fa,ja) and translocation of pro-Caspase 3(green) into the nucleus (DAPI, blue) after treatment (colocalization, cyan) as shown (c, g, k and ca, ga, ka). Photomicrographs delineate the colocalization of actin and active caspase-3 in the nucleus (see h, l and ha, la) upon compounds **11** and **13** treatments respectively. Images were obtained after 48 h of incubation SCC-12 cells with or without test compound and analyzed as in the materials and methods section.

Figure 5. Compounds **11** and **13** dose-dependently alter the actin cytoskeleton cell morphology and activate pro-apoptotic caspase-3 expression into the nucleus of SKMEL-28 cutaneous melanoma cancer

cell line. Immunofluorescent micrographs analyses indicate that compound **11** (A; e-l) and **13** (B; ea-la) compared to untreated controls; for **11** (a-d) and for **13** (aa-da) morphologically distorted the actin cytoskeleton as well as decreased the actin expression levels (red) in monolayer cultures of SKMEL-28 in a dose-dependent manner (0, $\frac{1}{2}$ IC₅₀, IC₅₀ and $1\frac{1}{2}$ IC₅₀; μ M), as shown (red; a, e, i and aa, ae, ai). Similarly, the effect of **11**(A) and **13**(B) in activation (green; b, f, j and ba, fa, ja) and translocation of pro-caspase 3 into the nucleus (DAPI, blue) after treatment (colocalization, cyan yellow) as shown (c, g, k and ca, ga, ka). Photomicrographs delineate the colocalization of actin and active caspase-3 (green) in the nucleus (see h, l and ha, la) upon compounds **11** and **13** treatments, respectively. Images were obtained after 48 h of incubation of SKMEL-28 cells with or without test compounds and analyzed as described in the materials and methods section.

The cysteinyl aspartate-specific protease family of apoptotic caspases, classified as initiators (caspases 8, 9, and 10) and executioners (caspases 3, 6, and 7), are often targeted for anticancer treatment, including skin tumor treatment.^{99,100} Using both the immunofluorescence microscopy (**Figure 4 and 5**) and Western blot analyses (**Figure 6 and 7**) of SCC-12 and SKMEL-28 skin cancer cell lines, the modulatory effects of compounds **11** and **13** treatments on the intrinsic and extrinsic apoptosis pathways were investigated by analyzing the protein expression levels of several key apoptosis-related markers. The assessed markers included an executioner pro- and cleaved (activated) forms of caspase -3 (by IF see above **Figure 4 and 5**; green), and an initiator pro- and cleaved caspase-9 as well as activation of PARP cleavage, evaluated by western blot analysis. In addition to the elevated protein expression levels of cleaved caspases-3 observed by immunofluorescence (**Figure 4 and 5**), the treatment of SCC-12 and SKMEL-28 cells with **11** and **13** resulted in significant activation of apoptosis, as evidenced by the increased activation of caspase-9, and PARP, as assessed by western blotting (**Figure 6**). The expression levels of cleaved caspase-9 and cleaved PARP were increased in a concentration-dependent manner compared to untreated controls.

Furthermore, the expression levels of important Bcl-2-family of proteins that regulate the induction of mitochondrial pathway of apoptosis, specifically Bax (pro-apoptotic), and Bcl-2 (anti-apoptotic),¹⁰¹ and PIM3, another apoptosis-related marker, were additionally studied in compounds **11** and **13** treated SCC-12 and SKMEL-28 skin cancer cell lines and compared with untreated controls.

Figure 6. Compounds 11 and 13 induce apoptosis by activating the extrinsic and intrinsic apoptotic pathway caspases in cutaneous melanoma (SKMel-28) and non-melanoma cancer cells (SCC-12). **A)** The blots show a dose-dependent effect (0, 1/2IC₅₀, IC₅₀ and 1 1/2IC₅₀; μM), of protein expression levels of markers of apoptosis, including pro- and-cleaved caspase 9, and PARP after 48 h of treatment. **B)** The data shown are representative immunoblots from three independent experiments with similar results. β-actin was used as a loading control to confirm the loading uniformity. The actual protein levels were normalized and expressed as a percentage of the loading control (mean ± SD of relative quantitative density values are plotted in the bar graphs). Statistical significance was assessed using one-way ANOVA and

Bonferroni's multiple comparison tests, $p < 0.01$ (**), $p < 0.001$ (***) and $p < 0.0001$ (****), were considered significant.

As shown in **Figure 7**, the treatment of both SCC-12 and SKMEL-28 cells with **11** and **13** significantly and dose-dependently increased the protein expression level of Bax while decreasing the expression levels of Bcl-2 and PIM3 compared to the untreated controls. Treatment with each of the two compounds resulted in a concentration-dependent increase in the Bax/Bcl-2 ratio (see **Figure 7**), supporting that **11** and **13** can induce the apoptosis of skin cancer cells, as observed herein in SCC-12 and SKMEL-28 skin cancer cell lines, through the intrinsic mitochondrial apoptotic pathway, leading to the activation of PARP.

As described above, uncontrolled cell proliferation and aberrant differentiation, which are the hallmarks of cancers¹⁰² including melanoma and non-melanoma skin cancers^{103,104} are often associated with dysregulated signaling pathways, such as the MAPK/ERK and PI3K/AKT pathways,^{103,104} which have been therapeutically targeted in several advanced melanoma clinical trials using a wide range of inhibitors.¹⁰³ In this study, the treatment of SCC-12 and SKMEL-28 with escalating concentrations (0, IC₅₀ and 1½IC₅₀) of **11** and **13** for 48 h resulted in a significant reduction in the protein levels of activated phosphorylated AKT, MAPK and mTOR targets when compared to the control group as indicated by the Western blot analysis. The protein expression levels of phosphorylated p90RSK (Ser³⁸⁰), Akt (Ser⁴⁷³), p44/42-MAPK (ERK1/2; Thr²⁰²/Try²⁰ and ribosomal protein S6(Ser^{235/236}) pathways targets were significantly suppressed in SCC-12 and SKMEL-28 cells treated with compound **11** and **13**, compared to the untreated controls as observed by Western blotting (**Figure 8**).

Figure 8. Compounds 11 and 13 inhibits the expression of markers of the AKT/ mTOR and MAPK pathway, including p90RSK, phosphorylated AKT, Phospho-p44/42 MAPK (Erk1/2) (Thr²⁰²/Tyr²⁰⁴), and Phospho-S6 Ribosomal Protein (Ser^{235/236}) in cutaneous melanoma (SKMel-28) and non-melanoma skin cancer cells (SCC-12). A) The blots show a dose-dependent effect (0, IC₅₀ and 1½IC₅₀; μM) of protein expression levels after 48 h of treatment. **B)** The data shown are representative immunoblots from three independent experiments with similar results. Rab-11 was used as loading control to confirm the loading uniformity. To obtain the bar graphs, the actual protein levels were normalized and expressed as a percentage of the loading control to obtain the bar graphs (mean ± SD of relative quantitative density values are plotted). Statistical significance was assessed using one-way ANOVA and Dunn's multiple comparison tests, $p < 0.01$ (**) and $p < 0.001$ (***), were considered significant.

3. Conclusion

Skin cancer is one of the most prevalent types of cancer in the United States, with approximately 9,500 people diagnosed with skin cancer every day.¹⁰⁵⁻¹⁰⁷ It is no secret that currently available treatments are hampered by drug resistance, side effects, low bioavailability, and high cost. Toward a goal of introducing new small molecule scaffolds into the skin cancer treatment pipeline, our screening efforts of a small library of over 90 compounds based on seven different skeletal frameworks have enabled the identification of 35 lead compounds with varying degrees of activities against melanoma (A375 and SKMEL-28) and non-melanoma (squamous carcinoma A431 and SCC-12) skin cancer cell lines. Many of these hit compounds displayed a useable anticancer activity, primarily against the squamous carcinoma A431 and SCC-12 cell lines, while exhibiting a superior safety profile than cisplatin (a well-known anticancer agent), used as a positive control, as indicated by their lack of activity against mammalian nontumorigenic immortalized HaCaT cells. The most promising compounds (**11** and **13**) were remarkably effective in inhibiting cell proliferation, inducing apoptosis, and suppressing cell migration and invasion *in vitro* in SK-MEL-28 and SCC-12 skin cancer cell lines. Data obtained from anti-proliferative/cytotoxic, scratch-wound healing, and colony formation assays, together with altered levels of aggregation of protein markers of disease, indicate that compounds **11** and **13** inhibit the

growth, migration and proliferation of cutaneous carcinoma cells. The results presented in this initial report suggest that compounds **11** and **13** modulate molecular signaling pathway targets involved in apoptosis and cancer progression. Furthermore, since many of the lead compounds uncovered during this study exhibited satisfactory pharmacokinetic and ADMET properties, this work provides a good framework toward a target-based design and the systematic synthesis of safer and more effective analogs for *in vivo* preclinical validation and mechanistic studies, including the analysis of differentially expressed proteins, activity-based protein profiling (ABPP) experiment, western blotting analysis and IHC analysis. There is no doubt that the wealth of information gathered here will be helpful in further studies towards the optimization of the hit molecules' activity and the determination of their putative drug target(s) and potential mechanism(s) of action.

4. Experimental section

4. 1. Synthesis

NMR data were collected on a Bruker Ascend™ 400 spectrometer operating at 400 MHz for ¹H and 100 MHz for ¹³C. The concentration of all samples was about 20 to 50 mg in 0.5 mL of CDCl₃. The NMR data were recorded at 300 K, with chemical shifts (δ) reported in parts per million (ppm) relative to TMS (δ_H 0.00 and δ_C 0.0) used as the internal standard, or residual chloroform (δ_H 7.28 and δ_C 77.2), and coupling constants (*J*) in hertz. The multiplicity listed as follow: s = singlet, d = doublet, t = triplet, q = quartet, q* = quintet, m = multiplet. Structures were confirmed based on 1D and 2D NMR data including proton, broadband carbon 13, COSY, NOESY, HSQC and HMBC. Reaction mixtures were monitored by TLC using silica gel 60 F254 plates or by a 200-MS Varian GC/MS ion trap mass spectrometer on which all the GC-MS spectra were recorded. The product(s) from each reaction was purified on a Teledyne ISCO RF200 CombiFlash, using a 40 g RediSepRF silica column, or by gravity and

flash column chromatography using type 60A silica gel (60-230 mesh). Single crystals of various samples suitable for X-ray structure determination were mounted on the tip of a glass fiber using silicon grease, and intensity data were recorded at 90 K on an STOE IPDS-2T diffractometer using graphite-monochromated MoK α radiation ($\lambda = 0.71073$ Å). Intensity data for all crystals were readily indexed and the structures were solved by direct method and refined by full-matrix least-squares techniques in the SHELTLX package of programs. The structure solutions revealed the positions of all non-hydrogen atoms within the crystal with some of the hydrogen positions. In subsequent refinement steps, the positions of the remaining hydrogen atoms were deduced from different Fourier syntheses. The software Diamond was utilized to create the graphic representations of the crystal structures with ellipsoid representations (50% probability level) for all non-hydrogen atoms.

All chemicals and solvents were purchased from major chemical suppliers and were used without further purification unless stated otherwise.

4.1.1. Methyl 2,6-dibromo-3,4,5-trimethoxybenzoate (**1**)⁴³

A mixture of methyl 3,4,5-trimethoxybenzoate (5 g, 22.1 mmol) and 1,3-dibromo-5,5-dimethylhydantoin also known as DBDMH (9.5 g, 33.2 mmol) in dichloromethane was allowed to stir at room temperature for 16 h. The reaction mixture was then filtered and concentrated under reduced pressure. The residue was purified on a silica gel column using a mixture of hexanes-dichloromethane (7:3) to yield the product as yellowish needles (7.4 g, 87%). mp 67.2 – 67.3 °C. ¹H NMR (CDCl₃, 400 MHz): δ 3.91 (6H, s), 3.95 (3H, s), 3.98 (3H, s). ¹³CNMR (CDCl₃, 100 MHz): δ 52.9, 61.0, 61.1, 109.5, 133.1, 148.3, 150.8, 165.9. GC-MS: m/z (%) 385 [M+H]⁺ (43), 384 [M]⁺ (100), 353 (25), 326 (15). The structure of this compound was unambiguously determined by single crystal X-ray diffraction. Crystal data: C₁₁H₁₂Br₂O₅, M_r = 384.03 g/mol, Crystal system monoclinic, Space group Cc, $a = 17.287(4)$ Å, $b = 8.9326(2)$ Å, $c = 9.0071(2)$ Å, $\alpha = 90^\circ$, $\beta = 105.90(3)^\circ$, $\gamma = 90^\circ$, $V = 1337.64(5)$ Å³, $T = 100(2)$ K, $Z = 4$, $D_x =$

1.91 g/cm³, μ = 6.070 mm⁻¹, F(000) = 752, λ = 0.71073 Å. Full-matrix least-squares refinement led to a final R = 0.028, wR = 0.069 and GOF = 1.049 (see supplemental data for the molecular representation at 50% probability level).⁴³

4.1.2. Methyl 3,4,5-trimethoxy-2-nitrobenzoate (**2**)⁴³

This compound was prepared as followed: to a solution of methyl 3,4,5-trimethoxybenzoate (5 g, 22.1 mmol) in glacial acetic acid (25 mL) in an ice bath, 1.1 mL of fuming nitric acid (1.55 g, 24.6 mmol) was carefully added (dropwise) over a period of 30 min. The resulting mixture was allowed to stir at room temperature for 2 h, and was then poured into icy water and neutralized with a saturated solution of sodium bicarbonate. It was then extracted with ethyl acetate, concentrated under reduced pressure and purified on a silica gel column using a mixture of hexane – ethyl acetate (8:2) to yield the product as colorless needles (1.32 g, 22%). mp 62.3 – 63.5 °C. ¹H NMR (CDCl₃, 400 MHz): δ 3.87 (3H, s), 3.95 (9H, s), 7.27 (1H, s). ¹³CNMR (CDCl₃, 100 MHz): δ 52.7, 56.3, 61.0, 62.4, 108.2, 117.2, 139.9, 145.3, 146.0, 153.8, 162.8. GC-MS: *m/z* (%) 272 [M+H]⁺ (15), 271 [M]⁺ (100), 256 (5), 241 (12), 210 (14), 195 (16). The structure of this compound was unambiguously determined by single crystal X-ray diffraction. Crystal data: C₁₁H₁₃NO₇, *M_r* = 271.22 g/mol, Crystal system monoclinic, Space group *C2/c*, *a* = 20.520(4) Å, *b* = 9.7438(2) Å, *c* = 24.434(5) Å, $\angle$ = 90°, $\angle$ = 99.46(3)°, $\angle$ = 90°, *V* = 4818.96(2) Å³, *T* = 100(2) K, *Z* = 14, *D_x* = 1.31 g/cm³, μ = 0.111 mm⁻¹, F(000) = 1988, λ = 0.71073 Å. Full-matrix least-squares refinement led to a final R = 0.032, wR = 0.099 and GOF = 1.033.⁴³

4.1.3. 4-Cyclohexenyl-*N,N*-dimethylaniline (**3**)⁴⁴

This compound was prepared by reacting *N,N*-dimethylaniline (5g, 41.3 mmol) with cyclohexanone (20.2 g, 206 mmol) in the presence of a catalytic amount of iodine (524 mg, 2.06 mmol). After purification on a silica gel column using a mixture of hexanes-ethyl acetate (97.5:2.5), compound **3** was obtained as a yellowish oil (4.5 g, 54 %). ¹H NMR (CDCl₃, 600 MHz): δ 1.68 (2H, m), 1.80 (2H, m), 2.23

(2H, m), 2.42 (2H, m), 2.96 (6H, s), 6.04 (1H, m), 6.74 (2H, d, $J = 8.9$ Hz), 7.33 (2H, d, $J = 8.9$ Hz). ^{13}C NMR (CDCl_3 , 100 MHz): δ 22.5, 23.4, 26.0, 27.5, 40.9, 112.4, 121.3, 125.5, 131.2, 136.0, 149.6. HRESI-MS: $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{14}\text{H}_{20}\text{N}$ 202.159026; Found 202.1621.

4.1.4. 2-Chloro-4-cyclohexenyl-*N*-ethylaniline (**4**)⁴⁴

This compound was obtained by reacting 2-chloro-*N*-ethylaniline (3.55 g, 22.8 mmol.) and cyclohexanone (11.2 g, 114 mmol) in the presence of a catalytic amount of iodine (290 mg, 1.14 mmol). After purification on a silica gel column using hexanes-ethyl acetate (95: 5), compound **4** was obtained as a brownish oil (2.15 g, 40%). ^1H NMR (CDCl_3 , 400 MHz): δ 1.29 (3H, t, $J = 8.0$ Hz), 1.63 (2H, m), 1.76 (2H, m), 2.15 (2H, m), 2.32 (2H, m), 3.19 (2H, q, $J = 8.0$ Hz), 4.12 (1H, brs, NH), 5.99 (1H, m), 6.59 (1H, d, $J = 8.0$ Hz), 7.18 (1H, dd, $J = 4.0$ and 8.0 Hz), 7.30 (1H, d, $J = 4.0$ Hz). ^{13}C NMR (CDCl_3 , 100 MHz): δ 14.7, 22.2, 23.1, 25.8, 27.3, 38.3, 110.8, 118.9, 122.3, 124.2, 125.6, 132.0, 135.2, 142.7. HRESI-MS: $[\text{M}]^+$ Calcd for $\text{C}_{14}\text{H}_{18}\text{ClN}$ 235.1123; Found 235.1121.

4.1.5. 6-Ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline (**5**)^{43,45}

p-Phenetidine (0.5 g, 3.6 mmol) and an excess of acetone (5 mL) were refluxed in toluene (10 mL) in the presence of a catalytic amount of iodine (92 mg, 0.36 mmol, 10 mol%) for 18 h. The solvent was then removed under reduced pressure on a rota-evaporator, and after purification on a silica gel column using hexanes-ethyl acetate (9: 1), compound **5** was obtained as brownish oil (380 mg, 48 %). ^1H NMR (CDCl_3 , 400 MHz): δ 1.28 (6H, s), 1.41 (3H, t, $J = 7.2$ Hz), 2.01 (3H, s), 3.42 (1H, brs, NH), 3.99 (2H, q, $J = 7.2$ Hz), 5.39 (1H, s), 6.42 (1H, d, $J = 7.2$ Hz), 6.41 (1H, dd, $J = 7.2$ and 4.0 Hz), 6.74 (1H, s). ^{13}C NMR (CDCl_3 , 100 MHz): δ 15.1, 18.6, 30.4, 51.7, 64.2, 111.1, 113.7, 114.4, 123.0, 128.6, 129.7, 137.5, 151.3. GC-MS: $[\text{M}]^+$ m/z (%): 217 (13), 216 (24), 201 (100), 173 (22), 144 (6).

4.1.6. 8-Ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline (**6**)^{43,45}

o-Phenetidine (0.5 g, 3.6 mmol) and an excess of acetone (5 mL) were refluxed in toluene (10 mL) in the presence of a catalytic amount of iodine (92 mg, 0.36 mmol, 10 mol%) for 18 h. The solvent was then removed under reduced pressure on a rota-evaporator, and after purification on a silica gel column using hexanes-ethyl acetate (9: 1), compound **6** was obtained as brownish oil (380 mg, 48 %). ¹H NMR (CDCl₃, 400 MHz): δ 1.33 (6H, s), 1.47 (3H, t, *J* = 7.2 Hz), 2.03 (3H, s), 4.01 (2H, q, *J* = 7.2 Hz), 4.29 (1H, brs, NH), 5.35 (1H, s), 6.60 (1H, d, *J* = 6.0 Hz), 6.71 (1H, t, *J* = 6.0 Hz), 6.80 (1H, d, *J* = 6.0 Hz). ¹³CNMR (CDCl₃, 100 MHz): δ 15.1, 18.8, 31.1, 51.3, 64.1, 110.8, 115.6, 116.2, 121.6, 128.2, 128.7, 133.2, 144. GC-MS: [M]⁺ *m/z* (%): 217 (6), 216 (14), 201 (100), 173 (20), 144 (6).

4.1.7. 8-Chloro-6-cyclopentenyl-2,3,4,5-tetrahydro-4,4-tetramethylene-1*H*-cyclopenta[*c*]quinoline (**7**)⁴⁵

This compound was obtained by reacting 4-chloroaniline (5 g, 39 mmol) and cyclopentanone (16.5 g, 196 mmol) in the presence of a catalytic amount of iodine (498 mg, 1.96 mmol). After purification on a silica gel column using hexanes-ethyl acetate (9:1), compound **7** was obtained as yellowish oil (7.4 g, 58 %). ¹H NMR (CDCl₃, 400 MHz): δ 1.67 – 1.70 (6H, m), 1.83 – 1.85 (2H, m), 1.95 – 2.03 (4H, m), 2.49 – 2.52 (2H, m), 2.54 – 2.56 (2H, m), 2.60 – 2.65 (4H, m), 4.64 (1H, brs, NH), 5.90 (1H, m), 6.73 (1H, d, *J* = 2.0 Hz), 6.84 (1H, d, *J* = 2.0 Hz). ¹³CNMR (CDCl₃, 100 MHz): δ 22.4, 23.3, 23.8, 31.4, 32.2, 33.9, 36.7, 39.6, 65.1, 121.1, 121.7, 122.0, 122.8, 125.9, 128.4, 132.0, 138.3, 140.1, 140.7. The *spiro*-quaternary carbon (C-4) appears at 65.1 ppm, while the g-HSQC and g-HMBC sequences enable to find the key correlation between the protons at δ 5.90 ppm (the proton on the cyclopentenyl double bond carried by the carbon at 125.9 ppm) and the quaternary aromatic carbon (C-6) at δ 122.8 ppm. HRESI-MS: [M + H]⁺ Calcd for C₂₁H₂₅NCl 326.167004; Found 326.1669.

4.1.8. 8-Cyclohexenyl-6-ethoxy-1,2-dihydro-2,2,4-trimethylquinoline (**8**)^{44,45}

This compound was obtained by reacting ethoxyquin (1.5 g, 6.9 mmol) and cyclohexanone (3.4 g, 34.5 mmol) in the presence of a catalytic amount of iodine (88 mg, 0.35 mmol). After purification on a silica gel column using hexanes-ethyl acetate (9: 1), compound **8** was obtained as yellowish oil (1.11 g, 54 %). ¹H NMR (CDCl₃, 400 MHz): δ 1.22 (6H, s), 1.36 (3H, t, *J* = 6.9 Hz), 1.68 – 1.69 (2H, m), 1.75 – 1.76 (2H, m), 1.98 (3H, s), 2.16 – 2.18 (4H, m), 3.42 (1H, brs, NH), 3.96 (2H, q, *J* = 6.9 Hz), 5.37 (1H, s), 5.71 (1H, m), 6.46 (1H, d, *J* = 2.8 Hz), 6.62 (1H, d, *J* = 2.8 Hz). ¹³CNMR (CDCl₃, 100 MHz): δ 15.2, 18.9, 22.2, 23.3, 25.5, 29.8, 30.0, 50.8, 51.5, 64.2, 109.5, 114.1, 123.4, 127.2, 129.1, 129.9, 134.0, 136.0, 150.7. The g-HSQC and g-HMBC sequences enable us to find the key correlation between the proton at δ 5.71 ppm (the proton on the cyclohexenyl double bond carried by the carbon at 127.2 ppm) and the quaternary aromatic carbon (C-6) at δ 129.1 ppm. HRESI-MS: [M + H]⁺ Calcd for C₂₀H₂₈NO 298.216541; Found 298.2158.

4.1.9. 6,8-Dicyclopentenyl-1,2-dihydro-2,2,4-trimethylquinoline (**9**)^{44,45}

This compound was obtained by reacting 2,2,4-trimethyl-1,2-dihydroquinoline (2.5 g, 14.4 mmol.) and cyclopentanone (6.07 g, 72.2 mmol) in the presence of a catalytic amount of iodine (183 mg, 0.722 mmol). After purification on a silica gel column using hexanes-ethyl acetate (97.5: 2.5), compound **9** was obtained as a yellowish oil (2.56 g, 58 %). ¹H NMR (CDCl₃, 400 MHz): δ 1.27 (6H, s), 1.51-1.55 (2H, m), 1.57-1.59 (2H, m), 1.63-1.68 (2H, m), 2.01-2.05 (2H, m), 2.02 (3H, s), 3.54-3.60 (2H, m), 2.65-2.70 (2H, m), 4.39 (1H, brs, NH), 5.33 (1H, s), 5.86-5.89 (2H, m), 6.84 (1H, d, *J* = 2.0 Hz), 6.87 (1H, d, *J* = 2.0 Hz). ¹³C NMR (CDCl₃, 100 MHz): δ 19.1, 23.4, 25.6, 31.1, 34.0, 34.9, 36.9, 45.7, 51.7, 121.3, 121.6, 122.1, 126.1, 127.9, 128.5, 129.2, 133.8, 138.5, 141.7. HRESI-MS: [M]⁺ Calcd for C₂₂H₂₇N 305.2144; Found 305.2152.

4.1.10. N1,N2-diethyl-4-methoxy-N2-(4-methoxyphenyl)benzene-1,2-diamine (**11**)⁴⁶

This compound was prepared by allowing *N*-ethyl-4-methoxyaniline (**10**) (1.3 g, 8.60 mmol.), obtained from Sigma-Aldrich, to stir for 20 minutes in an ice bath in the presence of sodium hydroxide (688 mg, 17.2 mmol, 2 equiv.), silver nitrate (73 mg, 0.43 mmol., 5 mol%) and water (15 mL). Then a 25% solution of sodium persulfate (1 equiv.) in water was added to the reaction, and the reaction was allowed to stir in an ice bath for 4 hours, with the temperature kept between 0 – 3 °C. The reaction mixture was then extracted with ethyl acetate (2 x 50 mL), dried with sodium sulfate, gravity filtered, and solvent was removed under reduced pressure. The residue was then purified on a silica gel column using hexanes-ethyl acetate (97.5: 2.5) to yield compound **11** as a yellowish oil (1.63 g, 63%). ¹H NMR (400 MHz, CDCl₃) 1.19 (6H, t, *J* = 8.0 Hz), 3.13 (2H, q, *J* = 7.9 Hz), 3.57 (2H, q, *J* = 7.8 Hz), 3.74 (3H, s), 3.77 (3H, s), 3.91 (1H, brs, NH), 6.66 (2H, d, *J* = 6.8 Hz), 6.72 (1H, d, *J* = 3.4 Hz), 6.79 (2H, d, *J* = 6.8 Hz), 7.29 (2H, d, *J* = 6.7 Hz). ¹³C NMR (100 MHz, CDCl₃): δ 12.8, 15.0, 39.1, 45.3, 55.8, 55.9, 112.3, 112.6, 114.7, 114.9, 115.5, 134.0, 140.6, 142.7, 151.7, 152.2. HRESI-MS: [M + H]⁺ Calcd for C₁₈H₂₄N₂O₂ 301.19105; Found 301.19224.

Compounds **12** – **35** were all prepared following a similar protocol.⁴⁷ The aniline derivative (1 eqv) and the phenol coupling partner (1 eqv) were dissolved in toluene, and 1 eqv of AgNO₃ was added. The mixture was then cooled in an ice bath and 3 eqv of H₂O₂ (30% in H₂O) was added dropwise with a Pasteur pipette. The reaction was then stirred for 6 h under atmospheric air during which the temperature was allowed to rise to room temperature. The reaction mixture was then extracted from water with 2 portions of 25 ml of ethyl acetate, and the combined extracts were dried over Na₂SO₄ and purified on a silica gel column using a mixture of hexanes-ethyl acetate to yield the expected product.

4.1.11. 1-(2-Amino-*N,N*,5-trimethylphenyl)naphthalen-2-ol (**12**)⁴⁷

N,N,4-trimethylaniline (500 mg, 3.70 mmol) and 2-naphthol (533 mg, 3.70 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (628 mg, 3.70 mmol) and H₂O₂ (1.26 g, 11.1 mmol). The

product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as clear colorless crystals (670 mg, 65 %). mp 171.8 – 172.2 °C. ¹H NMR (400 MHz, CDCl₃): δ (ppm) 2.32 (3H, s), 2.66 (6H, s), 7.15 – 7.28 (4H, m), 7.31 – 7.39 (2H, m), 7.76 – 7.83 (3H, m), 10.53 (1H, brs). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 20.7, 43.9, 118.2, 120.7, 121.0, 123.1, 125.4, 126.2, 128.2, 129.1, 129.4, 130.0, 130.6, 132.8, 133.5, 135.8, 147.4, 152.2. HRMS (ESI/Q-TOF): [M + H]⁺ Calcd for C₁₉H₂₀NO 278.1539; Found 278.1538. The structure of this compound was unambiguously determined by single crystal X-ray diffraction. Crystal data: C₁₉H₁₉NO, *M_r* = 277.35 g/mol, Crystal system monoclinic, Space group P 2₁/c, *a* = 9.302(5) Å, *b* = 8.916(4) Å, *c* = 19.097(9) Å, α = 90°, β = 104.096(1)°, γ = 90°, *V* = 1536.2(13) Å³, *T* = 294(2) K, *Z* = 4, *D_x* = 1.199 g/cm³, μ = 0.074 mm⁻¹, *F*(000) = 592, λ = 0.71073 Å. Full-matrix least-squares refinement led to a final *R* = 0.0443, *wR* = 0.1231 and GOF = 1.033. The crystal structure data are deposited in the Cambridge database (CCDC 821630).⁴⁸

4.1.12. 1-(2-Amino-5-ethoxy-*N,N*-dimethylphenyl)naphthalen-2-ol (**13**)⁴⁷

4-Ethoxy-*N,N*-dimethylaniline (500 mg, 3.03 mmol) and 2-naphthol (436 mg, 3.03 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (514 mg, 3.03 mmol) and H₂O₂ (1.03 g, 9.09 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as clear colorless crystals (653 mg, 70 %). mp 130.8 – 131.1 °C. ¹H NMR (400 MHz, CDCl₃): δ (ppm) 1.34 (3H, t, *J* = 6.8 Hz), 2.63 (6H, s), 3.94 (2H, q, *J* = 6.8 Hz), 6.95 (2H, m), 7.16 (1H, d, *J* = 8.8 Hz), 7.27 (1H, d, *J* = 8.8 Hz), 7.31 – 7.38 (2H, m), 7.76 – 7.81 (2H, m), 7.85 (1H, d, *J* = 8.0 Hz), 10.61 (1H, brs). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 14.8, 43.9, 63.8, 114.9, 119.0, 120.5, 120.8, 120.9, 123.0, 125.3, 126.1, 128.1, 129.4, 129.8, 132.1, 133.4, 143.3, 152.3, 154.4. HRMS (ESI/Q-TOF): [M + H]⁺ Calcd for C₂₀H₂₂NO₂ 308.1645; Found 308.1655. The structure of this compound was unambiguously determined by single crystal X-ray diffraction. Crystal data: C₂₀H₂₁NO₂, *M_r* = 307.38 g/mol, Crystal system monoclinic, Space group P 2₁/c, *a* = 9.267(3) Å, *b* = 7.093(2) Å, *c* = 25.135(8) Å, α = 90°, β = 91.104(4)°, γ = 90°, *V* = 1684.2(10) Å³, *T* = 294(2) K, *Z* = 4, *D_x* = 1.289 g/cm³, μ = 0.074 mm⁻¹, *F*(000) = 640, λ = 0.71073 Å. Full-matrix least-squares refinement led to a final *R* = 0.0443, *wR* = 0.1231 and GOF = 1.033. The crystal structure data are deposited in the Cambridge database (CCDC 821630).⁴⁸

$\gamma = 90^\circ$, $V = 1651.8(9) \text{ \AA}^3$, $T = 546(2) \text{ K}$, $Z = 4$, $D_x = 1.236 \text{ g/cm}^3$, $\vartheta_{\text{max}} = 28.96^\circ (\text{MoK}\alpha)$, $R = 0.0374$ for 4084 data and 208 refined parameters. The crystal structure data are deposited in the Cambridge database (CCDC 1442427).⁴⁷

4.1.13. 1-(2-Amino-N-benzyl-5-ethoxy-N-methylphenyl)naphthalen-2-ol (**14**)⁴⁷

N-benzyl-4-ethoxy-*N*-methylaniline (500 mg, 2.07 mmol) and 2-naphthol (299 mg, 2.07 mmol) were reacted in toluene (5 mL) in the presence of AgNO_3 (352 mg, 2.07 mmol) and H_2O_2 (705 mg, 6.22 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as brownish viscous oil (481 mg, 61 %). ^1H NMR (400 MHz, CDCl_3): δ (ppm) 1.36 (3H, t, $J = 6.8 \text{ Hz}$), 2.59 (3H, s), 3.75 (1H, d, $J = 13.2 \text{ Hz}$), 3.85 (1H, d, $J = 13.2 \text{ Hz}$), 3.96 (2H, q, $J = 6.8 \text{ Hz}$), 6.95 (3H, m), 7.00 (1H, d, $J = 2.7 \text{ Hz}$), 7.12 (1H, d, $J = 8.8 \text{ Hz}$), 7.19 (3H, m), 7.31 – 7.37 (3H, m), 7.80 (2H, d, $J = 8.6 \text{ Hz}$), 7.88 (1H, d, $J = 8.4 \text{ Hz}$), 10.01 (1H, brs). ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 14.8, 39.0, 62.1, 63.8, 115.0, 120.4, 120.6, 120.7, 120.9, 123.1, 125.1, 126.3, 127.5, 128.3, 129.4, 129.6, 130.0, 132.3, 133.4, 135.9, 143.0, 152.0, 154.7. HRMS (ESI/Q-TOF): $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{26}\text{H}_{26}\text{NO}_2$ 384.1958; Found 384.1973.

4.1.14. 1-[2-Amino-N-((2*E*)but-2-enyl)-5-ethoxy-N-methylphenyl]naphthalen-2-ol (**15**)⁴⁷

(*E*)-*N*-(but-2-enyl)-4-ethoxy-*N*-methylaniline (500 mg, 2.44 mmol) and 2-naphthol (351 mg, 2.44 mmol) were reacted in toluene (5 mL) in the presence of AgNO_3 (414 mg, 2.44 mmol) and H_2O_2 (829 mg, 7.31 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (542 mg, 64 %). ^1H NMR (400 MHz, CDCl_3): δ (ppm) 1.35 (3H, t, $J = 7.2 \text{ Hz}$), 1.57 (3H, d, $J = 6.0 \text{ Hz}$), 2.68 (3H, s), 3.19 – 3.30 (2H, m), 3.95 (2H, q, $J = 7.2 \text{ Hz}$), 5.20 – 5.27 (1H, m), 5.34 – 5.39 (1H, m), 6.92 – 6.97 (2H, m), 7.15 (1H, d, $J = 8.4 \text{ Hz}$), 7.24 – 7.36 (3H, m), 7.78 – 7.85 (3H, m), 10.45 (1H, s). ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 14.8, 17.7, 39.2, 53.4, 59.7, 64.3, 114.8,

120.1, 120.5, 120.9, 123.0, 125.3, 125.9, 126.1, 128.2, 129.5, 129.9, 130.7, 132.4, 133.4, 142.8, 152.1, 154.4. HRMS (ESI/Q-TOF): $[M + H]^+$ Calcd for $C_{23}H_{26}NO_2$ 348.1958; Found 348.1962.

4.1.15. 2-(2-Amino-5,*N,N*-trimethylphenyl)naphthalen-1-ol (**16**)⁴⁷

N,N,4-trimethylaniline (500 mg, 3.70 mmol) and 1-naphthol (533 mg, 3.70 mmol) were reacted in toluene (5 mL) in the presence of $AgNO_3$ (628 mg, 3.70 mmol) and H_2O_2 (1.26 g, 11.1 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as brownish crystals (540 mg, 53 %). mp 124.5 – 125.0 °C. 1H NMR (400 MHz, $CDCl_3$): δ (ppm). 2.36 (3H, s), 2.66 (6H, s), 7.10 – 7.17 (2H, m), 7.31 (1H, d, J = 1.6 Hz), 7.43 – 7.53 (4H, m), 7.77 – 7.80 (1H, m), 8.46 – 8.48 (1H, m), 11.92 (1H, brs). ^{13}C NMR (100 MHz, $CDCl_3$): δ (ppm) 20.8, 43.6, 118.1, 119.6, 120.7, 123.6, 125.0, 126.3, 126.9, 127.0, 128.4, 128.6, 134.1, 134.2, 134.4, 134.9, 145.8, 151.5. HRMS (ESI/Q-TOF): $[M + H]^+$ Calcd for $C_{19}H_{20}NO$ 278.1539; Found 278.1544. The structure of this compound was unambiguously determined by single crystal X-ray diffraction. Crystal data: $C_{19}H_{19}NO$, M_r = 277.35 g/mol, Crystal system orthorhombic, Space group $Pbca$, a = 7.633(2) Å, b = 15.037(4) Å, c = 27.693(8) Å, α = 90°, β = 90°, γ = 90°, V = 3178.5(16) Å³, T = 293(2) K, Z = 8, D_x = 1.159 g/cm³, ϑ_{max} = 23.29°(MoK α), R = 0.0690 for 2284 data and 190 refined parameters. The crystal structure data are deposited in the Cambridge database (CCDC 1442428).⁴⁷

4.1.16. 2'-(Dimethylamino)-5'-ethoxybiphenyl-2-ol (**17**)⁴⁷

4-Ethoxy-*N,N*-dimethylaniline (500 mg, 3.03 mmol) and phenol (285 mg, 3.03 mmol) were reacted in toluene (5 mL) in the presence of $AgNO_3$ (514 mg, 3.03 mmol) and H_2O_2 (1.03 g, 9.08 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (512 mg, 66 %). 1H NMR (400 MHz, $CDCl_3$): δ (ppm) 1.33 (3H, t, J = 7.2 Hz), 2.75 (6H, s), 3.89 (2H, q, J = 7.2 Hz), 6.45 (1H, d, J = 2.8 Hz), 6.60 (1H, dd, J = 2.8 and 8.8 Hz), 6.95 (1H, d, J = 8.8 Hz), 7.00 (1H, d, J = 7.6 Hz), 7.01 (1H, brs), 7.06 (1H, dd, J = 7.2 and 7.6 Hz), 7.29 (1H, d, J = 7.6

Hz), 7.31 (1H, d, J = 7.6 Hz). ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 14.8, 43.7, 63.7, 107.3, 109.1, 118.3, 119.4, 122.9, 129.6, 138.4, 150.1, 155.3, 158.5. HRMS (ESI/Q-TOF): $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{20}\text{NO}_2$ 258.1498; Found 258.1489.

4.1.17. 5-Bromo-2'-(dimethylamino)-5'-ethoxybiphenyl-2-ol (**18**)⁴⁷

4-Ethoxy-*N,N*-dimethylaniline (500 mg, 3.03 mmol) and 4-bromophenol (524 mg, 3.03 mmol) were reacted in toluene (5 mL) in the presence of AgNO_3 (514 mg, 3.03 mmol) and H_2O_2 (1.03 g, 9.08 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (602 mg, 59 %). ^1H NMR (400 MHz, CDCl_3): δ (ppm) 1.34 (3H, t, J = 7.2 Hz), 2.71 (6H, s), 3.91 (2H, q, J = 7.2 Hz), 6.46 (1H, d, J = 2.8 Hz), 6.64 (1H, dd, J = 2.8 and 8.8 Hz), 6.85 (1H, d, J = 8.8 Hz), 6.86 (1H, brs), 6.95 (1H, d, J = 8.8 Hz), 7.38 (2H, d, J = 8.8 Hz). ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 14.8, 43.6, 63.9, 107.7, 109.9, 115.1, 119.5, 119.6, 132.4, 138.5, 149.3, 154.6, 156.5. HRMS (ESI/Q-TOF): $[\text{M}]^+$ Calcd for $\text{C}_{16}\text{H}_{18}\text{BrNO}_2$ 336.0594; Found 336.0615.

4.1.18. 5-Chloro-2'-(dimethylamino)-5'-ethoxybiphenyl-2-ol (**19**)⁴⁷

4-ethoxy-*N,N*-dimethylaniline (500 mg, 3.03 mmol) and 4-chlorophenol (389 mg, 3.03 mmol) were reacted in toluene (5 mL) in the presence of AgNO_3 (514 mg, 3.03 mmol) and H_2O_2 (1.03 g, 9.08 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (532 mg, 60 %). ^1H NMR (400 MHz, CDCl_3): δ (ppm) 1.32 (3H, t, J = 7.2 Hz), 2.70 (6H, s), 3.88 (2H, q, J = 7.2 Hz), 6.47 (1H, d, J = 2.8 Hz), 6.63 (1H, dd, J = 2.8 and 8.8 Hz), 6.89 (1H, d, J = 8.8 Hz), 6.90 (1H, brs), 6.93 (1H, d, J = 8.8 Hz), 7.21 (2H, d, J = 9.2 Hz). ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 14.8, 43.5, 63.7, 107.7, 109.8, 119.0, 119.5, 127.6, 129.4, 138.4, 149.4, 154.6, 156.0. HRMS (ESI/Q-TOF): $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{19}\text{ClNO}_2$ 292.1099; Found 292.1116.

4.1.19. 2'-(Dimethylamino)-5'-ethoxy-5-methoxybiphenyl-2-ol (**20**)⁴⁷

4-Ethoxy-*N,N*-dimethylaniline (500 mg, 3.03 mmol) and 4-methoxyphenol (376 mg, 3.03 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (514 mg, 3.03 mmol) and H₂O₂ (1.03 g, 9.08 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (493 mg, 57 %). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 1.31 (3H, t, *J* = 7.2 Hz), 2.77 (6H, s), 3.76 (3H, s), 3.87 (2H, q, *J* = 7.2 Hz), 6.34 (1H, d, *J* = 2.8 Hz), 6.53 (1H, dd, *J* = 2.8 and 8.8 Hz), 6.85 (1H, d, *J* = 8.8 Hz), 6.87 (1H, brs), 6.93 (1H, d, *J* = 8.8 Hz), 6.98 (2H, d, *J* = 9.2 Hz). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 14.7, 43.7, 55.5, 63.6, 105.7, 107.7, 114.7, 119.1, 120.2, 137.6, 150.1, 151.7, 154.7, 155.7. HRMS (ESI/Q-TOF): [M + H]⁺ Calcd for C₁₇H₂₂NO₃ 288.1594; Found 288.1596.

4.1.20. 2'-(Dimethylamino)-5'-ethoxy-5-methylbiphenyl-2-ol (**21**)⁴⁷

4-Ethoxy-*N,N*-dimethylaniline (500 mg, 3.03 mmol) and 4-chlorophenol (327 mg, 3.03 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (514 mg, 3.03 mmol) and H₂O₂ (1.03 g, 9.08 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as colorless oil (573 mg, 70 %). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 1.31 (3H, t, *J* = 7.2 Hz), 2.31 (3H, s), 2.75 (6H, s), 3.88 (2H, q, *J* = 7.2 Hz), 6.40 (1H, d, *J* = 2.8 Hz), 6.57 (1H, dd, *J* = 2.8 and 8.8 Hz), 6.91 (1H, d, *J* = 7.2 Hz), 6.93 (1H, brs), 6.93 (1H, d, *J* = 7.6 Hz), 7.10 (2H, d, *J* = 8.4 Hz). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 14.8, 20.7, 43.8, 63.7, 106.6, 108.5, 118.6, 119.2, 130.1, 132.5, 138.0, 151.6, 154.6. HRMS (ESI/Q-TOF): [M + H]⁺ Calcd for C₁₇H₂₂NO₂ 272.1645; Found 272.1656.

4.1.21. 2'-(Dimethylamino)-5'-ethoxy-5-isopropylbiphenyl-2-ol (**22**)⁴⁷

4-Ethoxy-*N,N*-dimethylaniline (500 mg, 3.03 mmol) and 4-isopropylphenol (412 mg, 3.03 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (514 mg, 3.03 mmol) and H₂O₂ (1.03 g, 9.08 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (474 mg, 52 %). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 1.24 (6H, d, *J* = 7.2

Hz), 1.32 (3H, t, $J = 7.2$ Hz), 2.76 (6H, s), 2.88 (1H, m, $J = 7.2$ Hz), 3.89 (2H, q, $J = 7.2$ Hz), 6.42 (1H, d, $J = 2.8$ Hz), 6.57 (1H, dd, $J = 2.8$ and 8.8 Hz), 6.93 (1H, d, $J = 6.8$ Hz), 6.96 (1H, d, $J = 6.8$ Hz), 6.98 (1H, brs), 7.16 (2H, d, $J = 8.4$ Hz). ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 14.8, 24.2, 33.4, 43.8, 63.5, 106.7, 108.2, 118.6, 119.2, 127.5, 138.0, 143.6, 150.9, 154.6, 154.7. HRMS (ESI/Q-TOF): $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{26}\text{NO}_2$ 300.1958; Found 300.1954.

4.1.22. 4-Chloro-2'-(dimethylamino)-5'-ethoxybiphenyl-2-ol (**23**)⁴⁷

4-Ethoxy-*N,N*-dimethylaniline (500 mg, 3.03 mmol) and 3-chlorophenol (389 mg, 3.03 mmol) were reacted in toluene (5 mL) in the presence of AgNO_3 (514 mg, 3.03 mmol) and H_2O_2 (1.03 g, 9.08 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (509 mg, 58 %). ^1H NMR (400 MHz, CDCl_3): δ (ppm) 1.35 (3H, t, $J = 7.2$ Hz), 2.71 (6H, s), 3.92 (2H, q, $J = 7.2$ Hz), 6.49 (1H, d, $J = 2.8$ Hz), 6.66 (1H, dd, $J = 2.4$ and 8.8 Hz), 6.86 (1H, dd, $J = 1.6$ and 8.4 Hz), 6.95 (2H, m), 7.01 (1H, d, $J = 8.0$ Hz), 7.19 (1H, t, $J = 8.0$ Hz). ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 14.8, 43.6, 63.8, 108.1, 110.2, 115.9, 117.9, 119.6, 122.7, 130.3, 134.9, 138.6, 148.9, 154.6, 158.2. HRMS (ESI/Q-TOF): $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{19}\text{ClNO}_2$ 292.1099; Found 292.1107.

4.1.23. 4,5-Dichloro-2'-(dimethylamino)-5'-ethoxybiphenyl-2-ol (**24**)⁴⁷

4-Ethoxy-*N,N*-dimethylaniline (500 mg, 3.03 mmol) and 3,4-dichlorophenol (493 mg, 3.03 mmol) were reacted in toluene (5 mL) in the presence of AgNO_3 (514 mg, 3.03 mmol) and H_2O_2 (1.03 g, 9.08 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (531 mg, 54 %). ^1H NMR (400 MHz, CDCl_3): δ (ppm) 1.36 (3H, t, $J = 7.2$ Hz), 2.69 (6H, s), 3.93 (2H, q, $J = 7.2$ Hz), 6.50 (1H, d, $J = 2.4$ Hz), 6.68 (1H, dd, $J = 2.4$ and 8.8 Hz), 6.80 (1H, dd, $J = 2.8$ and 8.8 Hz), 6.96 (1H, d, $J = 8.8$ Hz), 7.04 (1H, d, $J = 2.8$ Hz), 7.32 (1H, d, $J = 8.8$ Hz). ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 14.8, 43.5, 63.8, 108.2, 110.5, 116.9, 119.1, 119.7, 125.7, 130.7, 132.9, 138.7, 148.4, 154.6, 156.6. HRMS (ESI/Q-TOF): $[\text{M}]^+$ Calcd for $\text{C}_{16}\text{H}_{17}\text{Cl}_2\text{NO}_2$ 326.0709; Found 326.0715.

4.1.24. 2'-(Dimethylamino)-5'-ethoxy-4,5-dimethylbiphenyl-2-ol (**25**)⁴⁷

4-Ethoxy-*N,N*-dimethylaniline (500 mg, 3.03 mmol) and 3,4-dimethylphenol (370 mg, 3.03 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (514 mg, 3.03 mmol) and H₂O₂ (1.03 g, 9.08 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as colorless oil (513 mg, 59 %). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 1.31 (3H, t, *J* = 7.2 Hz), 2.21 (6H, s), 2.76 (6H, s), 3.87 (2H, q, *J* = 7.2 Hz), 6.40 (1H, d, *J* = 2.8 Hz), 6.56 (1H, dd, *J* = 2.8 and 8.8 Hz), 6.78 (1H, dd, *J* = 2.8 and 8.4 Hz), 6.84 (1H, d, *J* = 2.4 Hz), 6.93 (1H, d, *J* = 8.8 Hz), 7.05 (1H, d, *J* = 8.4 Hz). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 14.8, 19.0, 19.9, 43.8, 63.6, 106.5, 108.1, 116.0, 119.1, 120.1, 130.5, 131.2, 137.9, 138.0, 151.0, 154.6, 154.7. HRMS (ESI/Q-TOF): [M + H]⁺ Calcd for C₁₈H₂₄NO₂ 286.1802; Found 286.1800.

4.1.25. 5'-Ethoxy-2'-(methyl(propyl)amino)biphenyl-2-ol (**26**)⁴⁷

4-Ethoxy-*N*-methyl-*N*-propylaniline (500 mg, 2.59 mmol) and phenol (243 mg, 2.59 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (439 mg, 2.59 mmol) and H₂O₂ (880 mg, 7.76 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (308 mg, 42 %). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.78 (3H, t, *J* = 7.2 Hz), 1.34 (3H, t, *J* = 7.2 Hz), 1.47 (2H, q, *J* = 7.6 Hz), 2.73 (3H, s), 2.94 (2H, t, *J* = 7.6 Hz), 3.91 (2H, q, *J* = 7.2 Hz), 6.48 (1H, d, *J* = 2.8 Hz), 6.62 (1H, dd, *J* = 2.8 and 8.8 Hz), 6.97 (2H, d, *J* = 8.4 Hz), 6.99 (1H, brs), 7.04 (1H, d, *J* = 7.2 Hz), 7.29 (2H, t, *J* = 8.0 Hz). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 11.5, 14.8, 20.3, 40.8, 57.7, 63.8, 107.5, 109.3, 117.9, 121.0, 122.5, 129.5, 137.8, 150.3, 154.6, 157.4. HRMS (ESI/Q-TOF): [M + H]⁺ Calcd for C₁₈H₂₄NO₂ 286.1802; Found 286.1801.

4.1.26. 5-Bromo-5'-ethoxy-2'-(methyl(propyl)amino)biphenyl-2-ol (**27**)⁴⁷

4-Ethoxy-*N*-methyl-*N*-propylaniline (500 mg, 2.59 mmol) and 4-bromophenol (448 mg, 2.59 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (439 mg, 2.59 mmol) and H₂O₂ (880 mg, 7.76

mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (381 mg, 40 %). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.75 (3H, t, *J* = 7.6 Hz), 1.35 (3H, t, *J* = 7.2 Hz), 1.42 (2H, q, *J* = 7.6 Hz), 2.68 (3H, s), 2.88 (2H, t, *J* = 7.6 Hz), 3.92 (2H, q, *J* = 7.2 Hz), 6.48 (1H, d, *J* = 2.4 Hz), 6.65 (1H, dd, *J* = 2.8 and 8.8 Hz), 6.81 (2H, d, *J* = 8.8 Hz), 6.96 (1H, d, *J* = 8.8 Hz), 7.37 (2H, d, *J* = 8.8 Hz). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 11.5, 14.9, 20.2, 40.7, 57.6, 63.8, 108.0, 110.1, 114.7, 119.2, 121.2, 132.3, 138.0, 149.5, 154.6, 156.9. HRMS (ESI/Q-TOF): [M]⁺ Calcd for C₁₈H₂₂BrNO₂ 364.0907; Found 364.0927.

4.1.27. 5'-Ethoxy-2'-(isobutyl(methyl)amino)biphenyl-2-ol (**28**)⁴⁷

4-Ethoxy-*N*-isobutyl-*N*-methylaniline (500 mg, 2.41 mmol) and phenol (227 mg, 2.41 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (410 mg, 2.41 mmol) and H₂O₂ (820 mg, 7.24 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as colorless oil (230 mg, 32 %). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.75 (6H, d, *J* = 6.8 Hz), 1.35 (3H, t, *J* = 6.8 Hz), 1.77 (1H, m), 2.70 (5H, m), 3.92 (2H, q, *J* = 7.2 Hz), 6.50 (1H, d, *J* = 2.8 Hz), 6.63 (1H, dd, *J* = 2.8 and 8.8 Hz), 6.91 (2H, d, *J* = 8.0 Hz), 6.98 (1H, d, *J* = 8.8 Hz), 7.02 (1H, d, *J* = 7.2 Hz), 7.25 – 7.29 (2H, m). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 14.8, 20.5, 26.5, 41.5, 63.6, 108.0, 109.8, 117.5, 121.3, 122.3, 129.4, 138.7, 150.1, 154.6, 157.7. EI-MS: [M]⁺ *m/z* 299.

4.1.28. 5-Bromo-5'-ethoxy-2'-(isobutyl(methyl)amino)biphenyl-2-ol (**29**)⁴⁷

4-Ethoxy-*N*-isobutyl-*N*-methylaniline (500 mg, 2.41 mmol) and 4-bromophenol (417 mg, 2.41 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (410 mg, 2.41 mmol) and H₂O₂ (820 mg, 7.24 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (208 mg, 23 %). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.73 (6H, d, *J* = 6.8 Hz), 1.36 (3H, t, *J* = 7.2 Hz), 1.75 (1H, m), 2.65 – 2.68 (5H, m), 3.93 (2H, t, *J* = 7.2 Hz), 6.50 (1H, d, *J* = 2.8 Hz), 6.66 (1H, dd, *J* = 2.8 and 8.8 Hz), 6.78 (2H, d, *J* = 9.2 Hz), 6.98 (1H, d, *J* = 8.8 Hz), 7.35 (2H, d, *J* =

9.2 Hz). ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 14.8, 20.5, 26.4, 29.7, 41.3, 63.5, 63.8, 108.3, 110.5, 114.3, 118.8, 121.4, 132.2, 138.9, 149.3, 154.6, 157.1. HRMS (ESI/Q-TOF): $[\text{M}]^+$ Calcd for $\text{C}_{19}\text{H}_{24}\text{BrNO}_2$ 378.1063; Found 378.1087.

4.1.29. 5-Bromo-5'-ethoxy-2'-(isopropyl(methyl)amino)biphenyl-2-ol (**30**)⁴⁷

4-Ethoxy-*N*-isopropyl-*N*-methylaniline (500 mg, 2.59 mmol) and 4-bromophenol (448 mg, 2.59 mmol) were reacted in toluene (5 mL) in the presence of AgNO_3 (439 mg, 2.59 mmol) and H_2O_2 (880 mg, 7.76 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (323 mg, 34 %). ^1H NMR (400 MHz, CDCl_3): δ (ppm) 0.97 (6H, d, J = 6.4 Hz), 1.36 (3H, t, J = 7.2 Hz), 2.55 (3H, s), 3.52 (1H, m), 3.93 (2H, q, J = 7.2 Hz), 6.49 (1H, d, J = 2.4 Hz), 6.65 (1H, dd, J = 2.4 and 8.8 Hz), 6.80 (2H, d, J = 8.8 Hz), 6.97 (1H, d, J = 8.8 Hz), 7.35 (2H, d, J = 8.8 Hz). ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 14.9, 18.8, 32.5, 52.7, 64.0, 108.0, 110.0, 114.6, 119.0, 122.8, 132.2, 138.1, 149.9, 154.9, 157.0. HRMS (ESI/Q-TOF): $[\text{M}]^+$ Calcd for $\text{C}_{18}\text{H}_{22}\text{BrNO}_2$ 364.0907; Found 364.0909.

4.1.30. 2'-(Benzyl(methyl)amino)-5'-ethoxybiphenyl-2-ol (**31**)⁴⁷

N-Benzyl-4-ethoxy-*N*-methylaniline (500 mg, 2.07 mmol) and phenol (195 mg, 2.07 mmol) were reacted in toluene (5 mL) in the presence of AgNO_3 (352 mg, 2.07 mmol) and H_2O_2 (705 mg, 6.22 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (274 mg, 40 %). ^1H NMR (400 MHz, CDCl_3): δ (ppm) 1.34 (3H, t, J = 7.2 Hz), 2.59 (3H, s), 3.91 (2H, q, J = 7.2 Hz), 4.12 (2H, s), 6.55 (1H, d, J = 2.4 Hz), 6.62 (1H, dd, J = 2.4 and 8.8 Hz), 6.93 (1H, d, J = 8.8 Hz), 6.97 (2H, d, J = 8.0 Hz), 7.05 – 7.11 (3H, m), 7.18 – 7.19 (3H, m), 7.29 (2H, dd, J = 7.6 and 8.4 Hz). ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 14.8, 39.8, 60.3, 63.9, 107.9, 109.6, 117.6, 121.1, 122.5, 126.8, 128.0, 128.7, 129.5, 137.9, 139.1, 149.7, 154.9, 157.7. HRMS (ESI/Q-TOF): $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{22}\text{H}_{24}\text{NO}_2$ 334.1802; Found 334.1814.

4.1.31. 2'-(Benzyl(methyl)amino)-5-bromo-5'-ethoxybiphenyl-2-ol (**32**)⁴⁷

N-Benzyl-4-ethoxy-*N*-methylaniline (500 mg, 2.07 mmol) and 4-bromophenol (358 mg, 2.07 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (352 mg, 2.07 mmol) and H₂O₂ (705 mg, 6.22 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (216 mg, 25 %). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 1.36 (3H, t, *J* = 7.2 Hz), 2.56 (3H, s), 3.93 (2H, q, *J* = 7.2 Hz), 4.08 (2H, s), 6.61 (1H, d, *J* = 2.8 Hz), 6.65 (1H, dd, *J* = 2.8 and 8.8 Hz), 6.81 (2H, d, *J* = 8.8 Hz), 6.95 (1H, d, *J* = 8.8 Hz), 7.04 (2H, d, *J* = 7.6 Hz), 7.19 – 7.23 (3H, m), 7.38 (2H, d, *J* = 8.8 Hz). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 14.8, 39.7, 60.1, 63.9, 108.3, 110.3, 114.6, 118.8, 121.2, 126.8, 128.0, 128.4, 132.3, 137.9, 138.5, 149.2, 154.8, 157.1. HRMS (ESI/Q-TOF): [M]⁺ Calcd for C₂₂H₂₂BrNO₂ 412.0907; Found 412.0908.

4.1.32. 5'-Ethoxy-2'-(ethyl(propyl)amino)biphenyl-2-ol (**33**)⁴⁷

4-Ethoxy-*N*-ethyl-*N*-propylaniline (500 mg, 2.41 mmol) and phenol (227 mg, 2.41 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (410 mg, 2.41 mmol) and H₂O₂ (820 mg, 7.24 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (279 mg, 47 %). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.77 (3H, t, *J* = 7.6 Hz), 0.94 (3H, t, *J* = 7.2 Hz), 1.35 (3H, t, *J* = 7.6 Hz), 1.39 (2H, m, *J* = 7.2 Hz), 2.93 (2H, m), 3.05 (2H, q, *J* = 7.2 Hz), 3.91 (2H, d, *J* = 7.2 Hz), 6.45 (1H, d, *J* = 2.8 Hz), 6.62 (1H, dd, *J* = 2.8 and 8.4 Hz), 6.92 (2H, d, *J* = 8.8 Hz), 6.99 (1H, d, *J* = 8.4 Hz), 7.04 (1H, d, *J* = 8.8 Hz), 7.27 (2H, t, *J* = 7.6 Hz). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 11.7, 12.3, 14.8, 20.4, 47.5, 54.9, 63.6, 107.6, 109.5, 117.8, 122.3, 124.0, 129.4, 135.4, 152.0, 155.1, 157.7. HRMS (ESI/Q-TOF): [M + H]⁺ Calcd for C₁₉H₂₆NO₂ 300.1958; Found 300.1976.

4.1.33. 5-Bromo-5'-ethoxy-2'-(ethyl(propyl)amino)biphenyl-2-ol (**34**)⁴⁷

4-Ethoxy-*N*-ethyl-*N*-propylaniline (500 mg, 2.41 mmol) and 4-bromophenol (417 mg, 2.41 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (410 mg, 2.41 mmol) and H₂O₂ (820 mg, 7.24 mmol).

The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (325 mg, 42 %). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.75 (3H, t, *J* = 7.6 Hz), 0.91 (3H, t, *J* = 7.2 Hz), 1.33 – 1.38 (5H, m), 2.88 – 2.92 (2H, m), 3.00 (2H, q, *J* = 7.2 Hz), 3.93 (2H, q, *J* = 7.2 Hz), 6.49 (1H, d, *J* = 2.8 Hz), 6.65 (1H, dd, *J* = 2.8 and 8.8 Hz), 6.78 (2H, d, *J* = 9.2 Hz), 6.99 (1H, d, *J* = 8.8 Hz), 7.35 (2H, d, *J* = 9.2 Hz). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 11.6, 12.2, 14.8, 20.5, 47.5, 54.8, 63.8, 108.0, 110.2, 114.5, 119.1, 123.9, 132.3, 135.6, 150.8, 155.1, 157.3. HRMS (ESI/Q-TOF): [M]⁺ Calcd for C₁₉H₂₄BrNO₂ 378.1063; Found 378.1069.

4.1.34. 5-Bromo-2'-(diethylamino)-5'-ethoxybiphenyl-2-ol (**35**)⁴⁷

4-Ethoxy-*N,N*-diethylaniline (500 mg, 2.59 mmol) and 4-bromophenol (448 mg, 2.59 mmol) were reacted in toluene (5 mL) in the presence of AgNO₃ (439 mg, 2.59 mmol) and H₂O₂ (880 mg, 7.76 mmol). The product was isolated by chromatography on a silica gel column using hexanes-ethyl acetate (9:1), and obtained as yellowish oil (432 mg, 46 %). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.92 (6H, t, *J* = 7.2 Hz), 1.35 (3H, t, *J* = 7.2 Hz), 3.02 (4H, q, *J* = 7.2 Hz), 3.92 (2H, q, *J* = 7.2 Hz), 6.50 (1H, d, *J* = 2.8 Hz), 6.65 (1H, dd, *J* = 2.8 and 8.8 Hz), 6.80 (2H, d, *J* = 8.8 Hz), 7.00 (1H, d, *J* = 8.8 Hz), 7.35 (2H, d, *J* = 9.2 Hz). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 12.3, 14.8, 46.9, 63.7, 107.9, 110.0, 114.5, 119.2, 124.0, 132.2, 134.9, 151.2, 155.2, 156.9. HRMS (ESI/Q-TOF): [M]⁺ Calcd for C₁₈H₂₂BrNO₂ 364.0907; Found 364.0910.

4.2. In vitro biological evaluation

4.2.1. Antibodies, chemicals and reagents

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO) and 4',6-diamidino-2-phenylindole (DAPI-#DUO82040), *in situ* mounting media and bovine serum albumin (BSA) were purchased from Sigma–Aldrich Chemical Company (St. Louis, MO, USA) and MP Biomedicals (Irvine, California, USA), respectively. Antibodies for immunoblotting and immunocytochemistry,

including caspase 3 (9662S), caspases 9 (#9502), Bcl-2 (2876S), Bax (2772S), β -Actin (13E5) Rabbit mAb #4970, pS6 (Ser235/236) #4858, a pan antibody mix of Phospho-Akt (Ser473)(D9E) XP® Rabbit mAb #4060, Phospho-p90RSK, Phospho-p44/42 MAPK(Erk 1/2) (Thr202/Tyr204), PARP Antibody #9542, Phospho-S6 Ribosomal Protein Detection Cocktail I (5301S), and horseradish peroxidase-conjugated (HRP) anti-mouse and anti-rabbit secondary antibodies were all obtained from Cell Signaling Technologies (Beverly, MA, USA). Mini-protean precast Tris-Glycine Gels (TGX) were from Bio-Rad (Bio-Rad Laboratories Inc., Hercules, California, USA). Radioimmunoprecipitation assay (RIPA) buffer and Pierce Bicinchoninic acid (BCA™) protein assay kit were purchased from ThermoFisher Scientific (Rockford, Illinois, USA). The SuperSignal™ West Pico PLUS Chemiluminescent substrate detection system was from ThermoFisher Scientific (Waltham, Massachusetts, USA). A 2% (w/v) Aqueous Solution of Gentian Violet and crystal violet were from Ricca Chemical Company (Arlington, TX, USA). Dulbecco's modified Eagle's medium (DMEM) and Roswell Park Memorial Institute Medium (RPMI 1640) were from Corning (Corning, Manassas, VA, USA). Epi-Life® Growth Medium with 60 μ M calcium and Cascade Biologist human keratinocyte growth supplement (HKGS) 100X (S-001–5) were from Life Technologies (Grand Island, NY, USA). The Dulbecco's phosphate-buffered saline (DPBS), phosphate buffer saline (PBS) 1X, defined trypsin inhibitor (DTI) 1X (R007-100), trypsin EDTA 0.25%, 1X (R25200-072), Trypsin neutralizer (TN) 1X (R-002–100), penicillin-streptomycin (Pen Strep, 15140–122) (PEST) 100X were purchased from Gibco, ThermoFisher Scientific (Rockford, IL, USA), and human keratinocyte growth supplement (HKGS) 100X (S-001–5) from Cascade Biologist were procured from VWR Corporation (Missouri, Texas, USA). USDA-approved Origin Fetal Bovine Serum (FBS) was procured from VWR Seradigm Life Science (Missouri, Texas, USA). The organic solvents including, ethanol (6183–10) and methanol (BDH 1135-4LP), were acquired from Macron Chemicals (Radnor, Pennsylvania, USA) and VWR (Missouri, Texas, USA), respectively.

4.2.2. Cell lines, cell cultures, cytotoxicity and viability evaluation assay

Human-derived GFP-expressing melanoma A375, and epidermoid carcinoma A431 cell lines were purchased from Angio-Proteomie (Boston, MA, USA). Human melanoma carcinoma SK-Mel-28 and Human immortalized keratinocytes (HaCaT) cell lines were acquired from American Type Culture Collection (ATCC; Manassas, VA, USA). Human cutaneous SCC cell line SCC-12 was generously provided by Dr. James G. Rheinwald¹⁰⁸ to Dr. Tatiana Efimova. Except SK-MEL-28, which was cultured in an RPMI-1640 medium supplemented with 5% FBS, all other human immortalized cell lines were grown and maintained in DMEM containing varying percentages of FBS; 5% FBS for A431, SCC-12 and HaCaT lines, while A375 was grown in 10% FBS. All culture media were routinely supplemented with 1% PEST 100X; 100U/ml penicillin, 100 µg/ml streptomycin, and cells were cultured in incubators maintained at 37 °C under an atmosphere of 95% humidity, 20% O₂ and 5% CO₂. The growth media of incubated cells were changed every 2-3 days until they attained 70-80% confluence, after which they were sub-cultured for experiments and/or re-passaging. DMSO was used as vehicle to prepare a 10 mM stock solution of the test compounds. Control cells were treated with the vehicle (DMSO) at concentrations (0.01-0.2%), not affecting cell viability.

Stock solutions (10 mM) were prepared by dissolving each compound to be screened in DMSO. From these 10 mM stock solutions, escalating concentrations were prepared using the corresponding cell growth media as a diluent, and the cells (65-75% confluent) were treated with (0-40 µM) or without the drug in sex-to -octuplicate and incubated for 48 h. All treatment protocols and controls were prepared as previously described.²⁵

The MTT assay method was performed to assess the potency and cytotoxic influence of the test compounds against two cutaneous melanoma (A375 and SK-MEL-28) and two non-melanoma (A431 and SCC-12) skin cancer cell-lines in addition to a control immortalized normal human epidermal

keratinocytes (HaCaT) cell line. Briefly, exponentially growing parent passage cells at 70-85% confluency were harvested, washed, counted using a hemocytometer, and individually seeded at a density of 2.5×10^3 Cells/well in a 96 well plate in 200 μ L of their respective growth media, incubated and monitored until reaching their log growth phase at over 70% confluent prior to treatment. All experimental treatment concentrations were repeated at least in 8-10 wells, and the experiment was repeated 6-8 times. Subsequently, the cells were harvested following the MTT protocol essentially as previously described,⁴¹ with absorbance measured at 562 nm wavelengths using a SynergyLX, multimode microplate reader (BioTek Instruments Inc., Winooski, VT, USA). The results from escalating concentration of each test and control (cisplatin) agent were analyzed using the zero drug control groups as the relative comparator and are expressed as a percentile following the equation: [(absorbance in treatment group/ absorbance in control) x 100%]. GraphPad Prism software version 9.3 (GraphPad Software, Inc., La Jolla, CA, USA) was then used to compute the various IC₅₀ values as earlier described.²⁵

4.2.3. Colony formation assay

This assay was performed to demonstrate the clonogenic potential of the active compounds on SCC-12 and SKMeL-28 cell lines, following a previously described protocol.²⁵ Briefly, 3000 viable cells treated with compounds **11** or **13** at varying concentrations (0, $\frac{1}{2}$ IC₅₀, IC₅₀ and $1\frac{1}{2}$ IC₅₀) for 48 h in a T-25 flask were harvested and seeded into a 10 cm² plate in quadruplicates in respective drug free growth medium. This was monitored with routine media change for 10-14 days until control cells reached about 90% confluency or cell plates formed about 50-150 colonies. The cell plates were then harvested by washing twice in 1XPBS, followed by fixing and staining in a submerged solution containing 0.5% gentian violet staining agent in 64% (v/v) methanol and 4% paraformaldehyde (4% PFA) for 45 to 60 minutes at room temperature. Stained cells were gently washed in tap water until

the solution became clear and were air-dried and imaged with a Nikon D7500 camera. Colonies were counted and analyzed using the count and Plot Histograms of Colony Size (countPHICS) analysis tool⁹⁹ and GraphPad Prism software version 9.1 (GraphPad Software, Inc., La Jolla, CA, USA), respectively. Statistical analyses data showed the mean $\pm$ SD of three independent experiments, comparing each treatment group to the DMSO group: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

4.2.4. Immunofluorescence Staining and immunocytochemical analysis of cells morphology by Actin and apoptosis by Caspase-3 activation.

Immunofluorescence analysis was employed to detect morphological and biochemical changes associated with the expression of apoptosis marker (Caspase 3) and the cell actin cytoskeleton reorganization following cells treatment. Briefly, cells pre-seeded into an 8-well chamber slide were treated with escalating concentrations (0, $\frac{1}{2}IC_{50}$, IC_{50} and $1\frac{1}{2}IC_{50}$) of the test compounds **11** or **13** for 48 h. The cells were washed and fixated using 4% PFA in PBS pH 7.4 for 20 to 30 min at room temperature, followed by permeabilization in 0.1% Triton X-100 stabilization buffer for 5 minutes, washed three times with cold 1xPBS, and non-specific binding was reduced using blocking buffer with 1%BSA for 30 min - 1 h. The cells were added to the respective primary antibodies [β -Actin or Caspase-3 at (1:1000 dilution)] for fluorescence staining, and cell slides were incubated overnight at 4 °C. Slides were subsequently washed thrice, and incubated with Texas Red@-X Goat Anti-mouse (dilution 1:600) and Alexa fluor Goat Anti-rabbit (dilution 1:600) for 2 h at room temperature. Slides were re-washed, and mounted using in situ mounting media containing phalloidin and 4',6-diamidino-2-phenylindole (DAPI). The mounted slides were visualized and imaged using the inverted fluorescence microscope Olympus IX71 equipped with a DP71 digital camera at 10x and 1.6x10x magnification. The images

captured were processed using the Cellsens 6 software and each experiment was performed three times.⁴¹

4.2.5. *In vitro* wound healing assay

The scratch wound healing assay was performed to evaluate compounds **11** or **13**'s ability to limit the migration and wound closure using a previously described protocol.²⁵ Briefly, a 24 well plate seeded with cells was incubated until a fully confluent monolayer of cells was scratched a straight line across the center using a sterile 200 µL Gilson pipette tip. Cells were washed gently to remove debris and detached cells and treated with **11** or **13** at escalating concentrations (0, $\frac{1}{2}$ IC₅₀, IC₅₀, and $1\frac{1}{2}$ IC₅₀). At times 0 h, 24 h, and 48 h, the wounded and re-epithelialization areas were imaged using an inverted phase-contrast microscope Olympus IX51 (Olympus America Inc., Center Valley, PA, USA) attached to an infinity 2 digital camera processed on an infinity analyze software version 6.5.6 (Teledyne Lumenera, Ottawa, Canada) and analyzed with Adobe Photoshop. The ImageJ software (NIH, Bethesda, MD) was then used to measure the migratory area of each treatment group at 24 h and 48 h, and are expressed as a percentage of wound surface at time 0 h.⁴¹

4.2.6. *Preparation of cell lysates, Western blot assay and analysis*

Cell lysate preparation and immunoblotting were performed. Briefly, lysates were prepared after subjecting 3x10 cm² plates seeded with about 3000 cells each and treated with varying concentrations (0, $\frac{1}{2}$ IC₅₀, IC₅₀ and $1\frac{1}{2}$ IC₅₀) of compounds for 48 h, following the reference protocol.²⁵ After treatment with compound **11** or **13**, the cell growth media were aspirated, and the cells were harvested by washing in cold 1xPBS (pH 7.4), and whole-cell, cytosolic and nuclear lysates were prepared as described earlier.²⁵ Cells were lysed by incubating in cell lysis RIPA buffer supplemented with protease and phosphatase inhibitors; 1 mM PMSF (phenylmethylsulfonyl fluoride), 10 mM RIPA buffer, 1 mM

protease inhibitor cocktail (1 mM EDTA, 20 mM NaF, 0.5% NP-40, 1% Triton X-100) (Roche) and 0.5% Na₃VO₄ on ice. The homogenate was then centrifuged at 14,000× g for 25 min at 4 °C, the supernatant was collected and the cleared lysate protein concentration was quantified using the BCA protein assay kit (Thermo Scientific, Pierce Rockford, IL) according to the manufacturer's protocol. The assay was performed using the Eppendorf BioPhotometer D30 and aliquoted and was immediately used or stored at – 80 °C for later use for western blot assay for further analysis as earlier described.²⁵

Western blotting and analysis were performed to identify the potential mechanisms and targeted pathways accounting for the observed biological responses for compounds **11** or **13**, following a previously described protocol.^{25,41} Western blot analysis was performed; accordingly, lysates were denatured in 2X Laemmli sample buffer and loaded (to resolve the equal amount of protein-25g) per lane using a KD 4–12% polyacrylamide ready mini-PROTEAN TGX gels electrophoresis, which causes separation based on molecular weight. The resolved proteins were transferred into nitrocellulose filter membrane using a Trans-Blot Turbo Transfer Pack. The presence of proteins was confirmed by using a ponceau staining before proceeding to washes (2X) under tap water and TBS-T wash buffer. Unspecific epitopes in the membrane were blocked with 5% BSA (for phospho-protein targets) or 5% non-fat dry milk/1% Tween 20; in 20 mM Tris-buffered saline (TBS or wash buffer) at room temperature on a rotating shaker for 45 min. The membranes were incubated overnight at 4 °C or 2 h at room temperature in the corresponding monoclonal or polyclonal primary antibodies (1:250 to 1:1000 dilution). Blots were then washed three times (5 min each) with PBST and incubated in anti-mouse or anti-rabbit horseradish-peroxidase (HRP) conjugated secondary antibody (1:2000 dilution). Afterward, blots were re-washed three times (5 min each), exposed to enhanced chemiluminescence plus west pico for 5 min and autoradiographed in a BioRad Gel-Doc System (Bio-Rad Laboratories Inc., Hercules, CA, USA). The loading consistency was verified utilizing the house-keeping proteins (Rab11 and β-Actin)

by stripping and re-probing blots with monoclonal β -actin primary antibody (Sigma, St Louis, MO) following the similar procedure as described earlier.^{25,41} The bands were then visualized and imaged using the Bio-Rad ChemiDoc™ detection system. Densitometry was done using Quantity One, the BioRad digitized scientific imaging analysis software system program. The Rab11 and β -actin data were used as a normalization factor and the linear range of the band densities were confirmed through multiple exposures of blot, and the analysis was based on three different experiments. As described earlier, The final data were analyzed for statistical differences using one-way ANOVA by the Graphpad Prism software.⁴¹

4.3. *In silico* screening assays

4.3.1. Target prediction and acquisition methodology

The SwissTargetPrediction database (<http://www.swisstargetprediction.ch/>) web server, which predicts the targets of bioactive molecules based on a combination of two-dimensional (2D) and 3D similarity measures with known ligands,^{58,109,110} was employed to screen and estimate the putative macromolecular targets of all the 90 derivatives synthesized. Briefly, these compounds' respective canonical simplified molecular input-line entry system (SMILES) structure formats were individually converted using the ChemDraw tool prior to importing into the SwissTargetPrediction network database to be queried. After the SMILES structures were uploaded to the database, the species "Homo sapiens" was selected, and a report of probable matched targets data was obtained. During target prediction, derivatives that possessed the highest probability to regulate identified targets under the consideration of probability >0.112, and the specific targets were selected based on values on predicted scores. The structure of the targets was retrieved from Protein Data Bank (PDB), and all PDB codes are available in the master excel sheet as supplementary data.

4.3.2. *In Silico molecular docking simulation methodology*

Molecular docking was used in this study to predict the binding interactions between ligands and their protein targets by calculating and predicting the conformation and directions of ligands at the active sites of proteins.¹¹¹ The credibility of the connection between the identified targets and the molecules screened was evaluated by docking each compound with the predicted target proteins. The molecular docking data were evaluated by selecting the known natural and clinical ligands of the studied targets and docking them as the positive longitudinal control. First, the SMILES structures of the commercially available clinical ligands used in the study were retrieved from the PubChem network database (<https://pubchem.ncbi.nlm.nih.gov/>),¹¹² together with those predicted for compounds to be screened, and the SMILES structures were converted into 3D conformation using OpenBabel. The suitable 3D crystallographic structure of the protein targets was retrieved from the RCSB Protein Data Bank (PDB) web (<https://www.rcsb.org/>),¹¹³ were predicted, and retrieved proteins (receptors) were in complex with other hetero-atoms and water molecules. After downloading the 3D PDB file of each of the structures of the targets, PyMOL was used to process it by removing the pre-complex water molecules, hetero-atoms and separating the structure of the protein and ligand (inhibitor) from the protein's-natural ligand complex alone. The separated natural inhibitor was considered a natural ligand in the docking separately to analyze the data. Both were then converted to PDBQT files using AutoDock Tools (ADT) that comes from an open-source software suite (the MGL tools 1.5.6)¹¹⁴ from Molecular Graphics Laboratory package from The Scripps Research Institute (<http://autodock.scripps.edu/>). During processing (to prepare the file suitable for docking), polar hydrogen was added to the separated protein structure before converting to PDBQT file. There was no need to add polar hydrogen in any ligands, but the torsion angle of each ligand was defined. While OpenBabel software (v2.2.1)

(<https://pyrx.sourceforge.io/>) was used for converting the SMILES format of all the ligands to generate their 3D conformations in PDB format, the program Raccoon¹¹⁵ was used to add the torsion angle that is important for docking, and once the torsion angle is found, was converted and saved in PDBQT file format like target, and was later used for docking as the ligand.

The grid box was set centered in the cartesian coordinate x-, y-, and z-directions of the docking site defined according to the pre-complexed ligand (natural ligand) of PDB files of each target after removing water molecules and hetero atoms for each of the natural ligand in its receptor, with a default grid point spacing of 0.375 Å. After preparing all the ligands and targets, the binding efficiency was predicted using the free accessible graphic user interface (GUI) AutoDock Vina software (v.1.2.0.)¹¹⁶ in Linux OS. After docking simulation, 10 other conformations of the docked ligands were obtained, each ligand with the minimum binding energy and RMSD value was chosen. The ligand and the target complexes (ligand-protein interactions) were then visualized using PyMOL,¹¹⁷ and processed using Discovery Studio (version 3.5, Dassault Systèmes BIOVIA, San Diego). During the docking process, the PDBQT files of these structures were used in AutoDock Vina software, as these files contained the information of potential ligands and receptors required for the process. After obtaining docking results and the binding energy of each ligand and receptors using AutoDock Vina, the results were output in PDBQT files and were uploaded to PyMOL software to establish the 3D data binding models. Binding energy was used as a docking score to evaluate the protein-ligand binding potential of the derivatives to the identified targets. Those results with value ≤ -8 were selected and considered to have a moderate binding potential and a stable combination irrespective of the cutoff reads of the natural and clinical ligands. The lower the binding energy (binding energy < -8.00 kcal/mol) indicates good binding strength, sufficient to move forward with the predicted target for each of the derivative.

4.3.3. *In silico* drug-likeness, pharmacokinetics and toxicity predictions

SwissADME was used to predict the ADME of each compound, where gastrointestinal absorption (GA), drug-likeness (DL), and other parameters were considered to define the bioactive compounds.^{58,110} The SwissADME online server predictor estimate information on the *in silico* pharmacokinetic properties, druglike nature, the logarithm of the partition coefficient (milog P), number of hydrogen-bond donors (HBDs), number of hydrogen-bond acceptors (HBAs), total topological polar surface area of the compound (TPSA), number of rotatable bonds (Nrotbs), and Lipinski's rule of five for drug likeliness.^{58,110}

4.3.4. Statistical analysis

As previously described, all statistical analyses were performed using GraphPad Prism Software version 9.1 (GraphPad Prism Inc., San Diego, CA, U.S.A.).²⁵ All quantitative and grouped data are expressed and presented as means $\pm$ standard deviation (SD) or $\pm$, standard error of the mean (SEM) from at least three independent experiments. The significance was analyzed by one-way ANOVA, Student t-test or ANOVA with Dunn's multiple comparison or Bonferroni's post hoc tests used to determine the difference between two or more groups. The following symbols represent the levels of statistical significance within each analysis: **p*-value <0.05, ***p*-value<0.01, ****p*-value <0.001 and *****p*-value <0.001.

Declaration of Competing Interest

The authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors acknowledge the financial support of NSF CHE-1954734 (awarded to JF). The following grants and funding partially supported this work: a Start-up fund from the University of Louisiana at Monroe (ULM) College of Pharmacy (COP), and a Faculty Research Seed grant #5CALHN-260615 awards from the ULMCOP; a Pilot and a full research project awards from a Louisiana Biomedical Research Network (LBRN)-IDeA Networks of Biomedical Research Excellence (INBRE) award from the National Institute of General Medical Sciences of the National Institutes of Health (NIGMS/NIH) grant number P2O GM103424-18, an LBRN-INBRE-COBRE Administrative Supplement Award from NIGMS/NIH grant 3P20GM103424-18S1, and a Louisiana Board of Regents Support Fund grant LEQSF (2021-24)-RD-A-22 (awarded to JCC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Appendix A

Supplementary data to this article can be found online at

References

- (1) Leiter, U.; Keim, U.; Garbe, C. Epidemiology of Skin Cancer: Update 2019. *Adv. Exp. Med. Biol.* **2020**, *1268*, 123-139.
- (2) Wright, C. Y.; Millar, D. A.; Wright, C. Y.; du, P. D. J.; du, P. D. J.; Norval, M. The Epidemiology of Skin Cancer and Public Health Strategies for Its Prevention in Southern Africa. *Int J Environ Res Public Health* **2020**, *17*.
- (3) Karimkhani, C.; Dellavalle, R. P.; Green, A. C.; Green, A. C.; Nijsten, T.; Weinstock, M. A.; Weinstock, M. A.; Dellavalle, R. P.; Dellavalle, R. P.; Naghavi, M.; Fitzmaurice, C.; Fitzmaurice, C. The global burden of melanoma: results from the Global Burden of Disease Study 2015. *Br J Dermatol* **2017**, *177*, 134-140.
- (4) Yousefi, H.; Mmohammadzadeh, S.; Irompour, A.; Shenassifam, N.; Roshandel, E.; Jalili, A. Overall study on molecular pathways of skin cancer derived from Ultraviolet radiation as an environmental threat. *Environ. Conserv. J.* **2015**, *16*, 547-555.
- (5) Rivas, M.; Rojas, E.; Araya, M. C.; Calaf, G. M. Ultraviolet light exposure, skin cancer risk and vitamin D production. *Oncol. Lett.* **2015**, *10*, 2259-2264.

- (6) Rigby, C. M.; Roy, S.; Deep, G.; Guillermo-Lagae, R.; Jain, A. K.; Dhar, D.; Orlicky, D. J.; Agarwal, C.; Agarwal, R. Role of p53 in silibinin-mediated inhibition of ultraviolet B radiation-induced DNA damage, inflammation and skin carcinogenesis. *Carcinogenesis* **2017**, *38*, 40-50.
- (7) Pavel, T. I.; Chircov, C.; Grumezescu, A. M.; Radulescu, M. Regenerative Wound Dressings for Skin Cancer. *Cancers (Basel)* **2020**, *12*.
- (8) Mulvaney, P. M.; Schmults, C. D. Molecular prediction of metastasis in cutaneous squamous cell carcinoma. *Curr. Opin. Oncol.* **2020**, *32*, 129-136.
- (9) Robertson, B. F.; Wokes, J. E. T.; Siddiqui, H. Management of Incompletely Excised Skin Tumors: Our Experience. *Dermatol. Surg.* **2018**, *44*, 365-369.
- (10) Zhi, D.; Yang, T.; Zhang, T.; Yang, M.; Zhang, S.; Donnelly, R. F. Microneedles for gene and drug delivery in skin cancer therapy. *J. Controlled Release* **2021**, *335*, 158-177.
- (11) Hwang, S.-Y.; Chae, J.-I.; Kwak, A.-W.; Lee, M.-H.; Shim, J.-H. Alternative options for skin cancer therapy via regulation of AKT and related signaling pathways. *Int. J. Mol. Sci.* **2020**, *21*, 6869.
- (12) Jain, R.; Sarode, I.; Singhvi, G.; Dubey, S. K. Nanocarrier Based Topical Drug Delivery- A Promising Strategy for Treatment of Skin Cancer. *Curr. Pharm. Des.* **2020**, *26*, 4615-4623.
- (13) Ascierto, P. A.; Garbe, C. Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from 'Immunotherapy Bridge.' *Immunotherapy* **2020**, *12*, 167-174.
- (14) Heppt, M. V.; Siepmann, T.; Engel, J.; Schubert-Fritschle, G.; Eckel, R.; Mirlach, L.; Kirchner, T.; Jung, A.; Gesierich, A.; Ruzicka, T.; Flaig, M. J.; Berking, C. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. *BMC Cancer* **2017**, *17*, 536/531-536/512.
- (15) Gutierrez-Castaneda, L. D.; Nova, J. A.; Tovar-Parra, J. D. Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review. *Melanoma Res* **2020**, *30*, 62-70.
- (16) Bai, X.; Kong, Y.; Chi, Z.; Sheng, X.; Cui, C.; Wang, X.; Mao, L.; Tang, B.; Li, S.; Lian, B.; Yan, X.; Zhou, L.; Dai, J.; Guo, J.; Si, L. MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. *Clin. Cancer Res.* **2017**, *23*, 6120-6127.
- (17) Pracht, M.; Mogha, A.; Lespagnol, A.; Fautrel, A.; Mouchet, N.; Le Gall, F.; Paumier, V.; Lefeuvre-Plesse, C.; Rioux-Leclerc, N.; Mosser, J.; Oger, E.; Adamski, H.; Galibert, M. D.; Lesimple, T. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. *J. Eur. Acad. Dermatol. Venereol.* **2015**, *29*, 1530-1538.
- (18) Dantonio, P. M.; Klein, M. O.; Freire, M. R. V. B.; Araujo, C. N.; Chiacetti, A. C.; Correa, R. G. Exploring major signaling cascades in melanomagenesis: a rationale route for targeted skin cancer therapy. *Biosci Rep* **2018**, *38*.
- (19) De Cicco, P.; Busa, R.; Ercolano, G.; Formisano, C.; Allegra, M.; Tagliatela-Scafati, O.; Ianaro, A. Inhibitory effects of cynaropicrin on human melanoma progression by targeting MAPK, NF- κ B, and Nrf-2 signaling pathways in vitro. *Phytother. Res.* **2021**, *35*, 1432-1442.
- (20) Sinkala, M.; Nkhoma, P.; Mulder, N.; Martin, D. P. Integrated molecular characterization of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies. *Commun. Biol.* **2021**, *4*, 9.
- (21) Alimirah, F.; Pulido, T.; Valdovinos, A.; Alptekin, S.; Chang, E.; Jones, E.; Diaz, D. A.; Flores, J.; Velarde, M. C.; Demaria, M.; Davalos, A. R.; Wiley, C. D.; Limbad, C.; Desprez, P.-Y.; Campisi, J. Cellular senescence promotes skin carcinogenesis through p38MAPK and p44/42MAPK signaling. *Cancer Res.* **2020**, *80*, 3606-3619.
- (22) Chamcheu, J. C.; Chaves-Rodriguez, M.-I.; Adhami, V. M.; Siddiqui, I. A.; Wood, G. S.; Longley, B. J.; Mukhtar, H. Upregulation of PI3K/AKT/mTOR, FABP5 and PPAR β/δ in human psoriasis and imiquimod induced murine psoriasisform dermatitis model. *Acta Derm.-Venereol.* **2016**, *96*, 854-856.
- (23) Chamcheu, J. C.; Roy, T.; Uddin, M. B.; Banang-Mbeumi, S.; Chamcheu, R.-C. N.; Walker, A. L.; Liu, Y.-Y.; Huang, S. Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy. *Cells* **2019**, *8*, 803.

- (24) Wei, T.; Choi, S.; Buehler, D.; Anderson, R. A.; Lambert, P. F. A PI3K/AKT scaffolding protein, IQ motif-containing GTPase associating protein 1 (IQGAP1), promotes head and neck carcinogenesis. *Clin. Cancer Res.* **2020**, *26*, 301-311.
- (25) Roy, T.; Boateng, S. T.; Banang-Mbeumi, S.; Singh, P. K.; Basnet, P.; Chamcheu, R.-C. N.; Ladu, F.; Chauvin, I.; Spiegelman, V. S.; Hill, R. A.; Kousoulas, K. G.; Nagalo, B. M.; Walker, A. L.; Fotie, J.; Murru, S.; Sechi, M.; Chamcheu, J. C. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers. *Bioorg. Chem.* **2021**, *107*, 104595.
- (26) Chamcheu, J. C.; Adhami, V. M.; Esnault, S.; Sechi, M.; Siddiqui, I. A.; Satyshur, K. A.; Syed, D. N.; Dodwad, S.-J. M.; Chaves-Rodriguez, M.-I.; Longley, B. J.; Wood, G. S.; Mukhtar, H. Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice. *Antioxid. Redox Signaling* **2017**, *26*, 49-69.
- (27) Eberle, J.; Fecker, L. F.; Forscher, T.; Ulrich, C.; Rowert-Huber, J.; Stockfleth, E. Apoptosis pathways as promising targets for skin cancer therapy. *Br J Dermatol* **2007**, *156 Suppl 3*, 18-24.
- (28) Athar, M.; Li, C.; Kim, A. L.; Spiegelman, V. S.; Bickers, D. R. Sonic Hedgehog Signaling in Basal Cell Nevus Syndrome. *Cancer Res.* **2014**, *74*, 4967-4975.
- (29) Noubissi, F. K.; Yedjou, C. G.; Spiegelman, V. S.; Tchounwou, P. B. Cross-talk between Wnt and Hh signaling pathways in the pathology of basal cell carcinoma. *Int. J. Environ. Res. Public Health* **2018**, *15*, 1442/1441-1442/1413.
- (30) Tran, P. H. L.; Duan, W.; Lee, B.-J.; Tran, T. T. D. Nanogels for Skin Cancer Therapy via Transdermal Delivery: Current Designs. *Curr. Drug Metab.* **2019**, *20*, 575-582.
- (31) Ma, X.; Qu, Q.; Zhao, Y. Targeted Delivery of 5-Aminolevulinic Acid by Multifunctional Hollow Mesoporous Silica Nanoparticles for Photodynamic Skin Cancer Therapy. *ACS Appl. Mater. Interfaces* **2015**, *7*, 10671-10676.
- (32) Feoktistova, M.; Panayotova-Dimitrova, D. Overcoming cell death resistance in skin cancer therapy: Novel translational perspectives. *Exp Dermatol* **2017**, *26*, 854-857.
- (33) Dong, L.; Li, Y.; Li, Z.; Xu, N.; Liu, P.; Du, H.; Zhang, Y.; Huang, Y.; Zhu, J.; Ren, G.; Xie, J.; Wang, K.; Zhou, Y.; Shen, C.; Zhu, J.; Tao, J. Au nanocage-strengthened dissolving microneedles for chemo-photothermal combined therapy of superficial skin tumors. *ACS Appl. Mater. Interfaces* **2018**, *10*, 9247-9256.
- (34) Liu, J.; Sun, L.; Li, L.; Zhang, R.; Xu, Z. P. Synergistic Cancer Photochemotherapy via Layered Double Hydroxide-Based Trimodal Nanomedicine at Very Low Therapeutic Doses. *ACS Appl. Mater. Interfaces* **2021**, *13*, 7115-7126.
- (35) Silk, T.; Wu, J. Cutaneous toxicities of targeted therapies in the treatment of hepatocellular carcinoma. *Hepatoma Res.* **2020**, *6*, 1-16.
- (36) Liu, P.; Zhao, L.; Pol, J.; Levesque, S.; Petrazzuolo, A.; Pfirschke, C.; Engblom, C.; Rickelt, S.; Yamazaki, T.; Iribarren, K.; Senovilla, L.; Bezu, L.; Vacchelli, E.; Sica, V.; Melis, A.; Martin, T.; Lin, X.; Yang, H.; Li, Q.; Chen, J.; Durand, S.; Aprahamian, F.; Lefevre, D.; Broutin, S.; Paci, A.; Bongers, A.; Minard-Colin, V.; Tartour, E.; Zitvogel, L.; Apetoh, L.; Ma, Y.; Pittet, M. J.; Kepp, O.; Kroemer, G. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. *Nat. Commun.* **2019**, *10*, 1-17.
- (37) Garg, A. D.; More, S.; Rufo, N.; Mece, O.; Sassano, M. L.; Agostinis, P.; Zitvogel, L.; Kroemer, G.; Galluzzi, L. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. *Oncol Immunology* **2017**, *6*, e1386829/1386821-e1386829/1386818.
- (38) Franzin, R.; Netti, G. S.; Spadaccino, F.; Porta, C.; Gesualdo, L.; Stallone, G.; Castellano, G.; Ranieri, E. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand. *Front. Immunol.* **2020**, *11*, 574271.
- (39) Chamcheu, J. C.; Siddiqui, I. A.; Adhami, V. M.; Esnault, S.; Bharali, D. J.; Babatunde, A. S.; Adame, S.; Massey, R. J.; Wood, G. S.; Longley, B. J.; Mousa, S. A.; Mukhtar, H. Chitosan-based nanoformulated (-)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis. *Int. J. Nanomed.* **2018**, *13*, 4189-4206.

- (40) Sanna, V.; Singh, C. K.; Jashari, R.; Adhami, V. M.; Chamcheu, J. C.; Rady, I.; Sechi, M.; Mukhtar, H.; Siddiqui, I. A. Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy. *Sci. Rep.* **2017**, *7*, 41573.
- (41) Chamcheu, J. C.; Esnault, S.; Adhami, V. M.; Noll, A. L.; Banang-Mbeumi, S.; Roy, T.; Singh, S. S.; Huang, S.; Kousoulas, K. G.; Mukhtar, H. Fisetin, a 3,7,3',4'-tetrahydroxyflavone inhibits the PI3K/Akt/mTOR and MAPK pathways and ameliorates psoriasis pathology in 2D and 3D organotypic human inflammatory skin models. *Cells* **2019**, *8*, 1089.
- (42) Syed, D. N.; Chamcheu, J.-C.; Khan, M. I.; Sechi, M.; Lall, R. K.; Adhami, V. M.; Mukhtar, H. Fisetin inhibits human melanoma cell growth through direct binding to p70S6K and mTOR: Findings from 3-D melanoma skin equivalents and computational modeling. *Biochem. Pharmacol. (Amsterdam, Neth.)* **2014**, *89*, 349-360.
- (43) Fotie, J.; Olvera, A.; Ayer, S. K.; Djieutedjeu, H.; Poudeu, P. F. P. Synthesis and Crystal Structures of Methyl 3,4,5-Trimethoxybenzoate and 1,2-Dihydro-2,2,4-Trimethylquinoline Derivatives. *J. Chem. Crystallogr.* **2015**, *45*, 1-8.
- (44) Fotie, J.; Ayer, S. K.; Poudel, B. S.; Reid, C. S. Iodine-catalyzed cycloalkenylation of dihydroquinolines and arylamines through a reaction with cyclic ketones under neat conditions. *Tetrahedron Lett.* **2013**, *54*, 7069-7073.
- (45) Fotie, J.; Kemami Wangun, H. V.; Fronczek, F. R.; Massawe, N.; Bhattarai, B. T.; Rhodus, J. L.; Singleton, T. A.; Bohle, D. S. Unexpected 5,6,7,8,9,10-Hexahydro-6,6-pentamethylenephenanthridines and 2,3,4,5-Tetrahydro-4,4-tetramethylene-1H-cyclopenta[c]quinolines from Skraup-Doebner-Von Miller Quinoline Synthesis and Their Implications for the Mechanism of That Reaction. *J. Org. Chem.* **2012**, *77*, 2784-2790.
- (46) Fotie, J.; Rhodus, J. L.; Taha, H. A.; Reid, C. S. C-N Coupling of 1,2-dihydro-2,2,4-trimethylquinoline derivatives via a silver(I)-catalyzed direct functionalization of a C-H bond. *Heteroat. Chem.* **2012**, *23*, 598-604.
- (47) Berkessa, S. C.; Clarke, Z. J. F.; Fotie, J.; Bohle, D. S.; Grimm, C. C. Silver(I)-mediated regioselective oxidative cross-coupling of phenol and aniline derivatives resulting in 2'-aminobiphenyl-2-ols. *Tetrahedron Lett.* **2016**, *57*, 1613-1618.
- (48) Chandrasekharam, M.; Chiranjeevi, B.; Gupta, K. S. V.; Sridhar, B. Iron-catalyzed regioselective direct oxidative aryl-aryl cross-coupling. *J. Org. Chem.* **2011**, *76*, 10229-10235.
- (49) Abd-Rabou, A. A.; Shalby, A. B.; Ahmed, H. H. Anti-cancer activity of quercetin, gallic acid, and ellagic acid against HepG2 and hct 116 cell lines: in vitro. *Int. J. Pharma Bio Sci.* **2016**, *7*, 584-592.
- (50) Alfaifi, M. Y.; Elbehairi, S. I.; Shati, A. A.; Fahmy, U. A.; Alhakamy Shadab, N. A. Ellagic acid loaded TPGS micelles for enhanced anti-cancer activities in ovarian cancer. *Int. J. Pharmacol.* **2020**, *16*, 63-71.
- (51) Aslan, A.; Gok, O.; Beyaz, S.; Arslan, E.; Erman, O.; Agca, C. A. The preventive effect of ellagic acid on brain damage in rats via regulating of Nrf-2, NF- κ B and apoptotic pathway. *J. Food Biochem.* **2020**, *44*, e13217.
- (52) Bisen, P. S.; Bundela, S. S.; Sharma, A. Ellagic acid - chemopreventive role in oral cancer. *J. Cancer Sci. Ther.* **2012**, *4*, 023-030.
- (53) Byrne, R.; Schneider, G. In silico target prediction for small molecules. *Methods Mol. Biol. (N. Y., NY, U. S.)* **2019**, *1888*, 273-309.
- (54) Chaudhari, R.; Tan, Z.; Huang, B.; Zhang, S. Computational polypharmacology: a new paradigm for drug discovery. *Expert Opin. Drug Discovery* **2017**, *12*, 279-291.
- (55) Lushington, G. H.; Dong, Y.; Theertham, B. Chemical Informatics and the Drug Discovery Knowledge Pyramid. *Comb. Chem. High Throughput Screening* **2013**, *16*, 764-776.
- (56) Cereto-Massague, A.; Ojeda, M. J.; Valls, C.; Mulero, M.; Pujadas, G.; Garcia-Vallve, S. Tools for in silico target fishing. *Methods (Amsterdam, Neth.)* **2015**, *71*, 98-103.
- (57) Ding, H.; Takigawa, I.; Mamitsuka, H.; Zhu, S. Similarity-based machine learning methods for predicting drug-target interactions: a brief review. *Brief Bioinform* **2014**, *15*, 734-747.
- (58) Daina, A.; Michielin, O.; Zoete, V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. *Nucleic Acids Res.* **2019**, *47*, W357-W364.

- (59) Armstrong, M. S.; Finn, P. W.; Morris, G. M.; Richards, W. G. Improving the accuracy of ultrafast ligand-based screening: incorporating lipophilicity into ElectroShape as an extra dimension. *J. Comput.-Aided Mol. Des.* **2011**, *25*, 785-790.
- (60) Armstrong, M. S.; Morris, G. M.; Finn, P. W.; Sharma, R.; Moretti, L.; Cooper, R. I.; Richards, W. G. ElectroShape: fast molecular similarity calculations incorporating shape, chirality and electrostatics. *J. Comput.-Aided Mol. Des.* **2010**, *24*, 789-801.
- (61) Johnson, M.; Lajiness, M.; Maggiore, G. Molecular similarity: a basis for designing drug screening programs. *Prog. Clin. Biol. Res.* **1989**, *291*, 167-171.
- (62) Adinolfi, B.; Romanini, A.; Vanni, A.; Martinotti, E.; Chicca, A.; Fogli, S.; Nieri, P. Anticancer activity of anandamide in human cutaneous melanoma cells. *Eur. J. Pharmacol.* **2013**, *718*, 154-159.
- (63) Khasabova, I. A.; Khasabov, S. G.; Harding-Rose, C.; Coicou, L. G.; Seybold, B. A.; Lindberg, A. E.; Steevens, C. D.; Simone, D. A.; Seybold, V. S. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. *J. Neurosci.* **2008**, *28*, 11141-11152.
- (64) Wohlman, I. M.; Composto, G. M.; Heck, D. E.; Heindel, N. D.; Lacey, C. J.; Guillon, C. D.; Casillas, R. P.; Crutch, C. R.; Gerecke, D. R.; Laskin, D. L.; Joseph, L. B.; Laskin, J. D. Mustard vesicants alter expression of the endocannabinoid system in mouse skin. *Toxicol. Appl. Pharmacol.* **2016**, *303*, 30-44.
- (65) Casanova, M. L.; Blazquez, C.; Martinez-Palacio, J.; Villanueva, C.; Fernandez-Acenero, M. J.; Huffman, J. W.; Jorcano, J. L.; Guzman, M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. *J. Clin. Invest.* **2003**, *111*, 43-50.
- (66) Spanbroek, R.; Stark, H.-J.; Janssen-Timmen, U.; Kraft, S.; Hildner, M.; Andi, T.; Bosch, F.-X.; Fusenig, N. E.; Bieber, T.; Radmark, O.; Samuelsson, B.; Habenicht, A. J. R. 5-lipoxygenase expression in Langerhans cells of normal human epidermis. *Proc. Natl. Acad. Sci. U. S. A.* **1998**, *95*, 663-668.
- (67) Katikaneni, A.; Jelcic, M.; Gerlach, G. F.; Ma, Y.; Overholtzer, M.; Niethammer, P. Lipid peroxidation regulates long-range wound detection through 5-lipoxygenase in zebrafish. *Nat. Cell Biol.* **2020**, *22*, 1049-1055.
- (68) Jeric, I.; Maurer, G.; Cavallo, A. L.; Raguz, J.; Desideri, E.; Tarkowski, B.; Parrini, M.; Fischer, I.; Zatloukal, K.; Baccarini, M. A cell-autonomous tumor suppressor role of RAF1 in hepatocarcinogenesis. *Nat. Commun.* **2016**, *7*, 13781.
- (69) Donati, M.; Michal, M.; Donati, M.; Martinek, P.; Kastnerova, L.; Michal, M.; Kazakov, D. V.; Martinek, P.; Kastnerova, L.; Michal, M.; Kazakov, D. V.; Persichetti, P.; Michal, M. RAF1 Gene Fusions as a Possible Driver Mechanism in Rare BAP1-Inactivated Melanocytic Tumors: A Report of 2 Cases. *Am J Dermatopathol* **2020**, *42*, 961-966.
- (70) Kaczorowski, M.; Biecek, P.; Donizy, P.; Pieniazek, M.; Matkowski, R.; Halon, A. ROCK1 and ROCK2 are down-regulated in aggressive and advanced skin melanomas - a clinicopathological perspective. *Anticancer Res.* **2020**, *40*, 1931-1942.
- (71) Chang, F.; Zhang, Y.; Mi, J.; Zhou, Q.; Bai, F.; Xu, X.; Fisher, D. E.; Sun, Q.; Wu, X. ROCK inhibitor enhances the growth and migration of BRAF-mutant skin melanoma cells. *Cancer Sci.* **2018**, *109*, 3428-3437.
- (72) Tho, L. M.; Libertini, S.; Rampling, R.; Sansom, O.; Gillespie, D. A. Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis. *Oncogene* **2012**, *31*, 1366-1375.
- (73) Wang, Z.; Forsund, M. S.; Trope, C. G.; Nesland, J. M.; Holm, R.; Slipicevic, A. Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro. *Cancer Med.* **2018**, *7*, 3955-3964.
- (74) Martens, M. C.; Seebode, C.; Lehmann, J.; Emmert, S. Photocarcinogenesis and skin cancer prevention strategies: an update. *Anticancer Res.* **2018**, *38*, 1153-1158.
- (75) Hwang, M. K.; Kang, N. J.; Heo, Y.-S.; Lee, K. W.; Lee, H. J. Fyn kinase is a direct molecular target of delphinidin for the inhibition of cyclooxygenase-2 expression induced by tumor necrosis factor- α . *Biochem. Pharmacol.* **2009**, *77*, 1213-1222.
- (76) Fathi, A. T.; Le, L.; Hasserjian, R. P.; Sadrzadeh, H.; Levis, M.; Chen, Y.-B. FLT3 inhibitor-induced neutrophilic dermatosis. *Blood* **2013**, *122*, 239-242.

- (77) Brummer, T.; Martin, P.; Herzog, S.; Misawa, Y.; Daly, R. J.; Reth, M. Functional analysis of the regulatory requirements of B-Raf and the B-RafV600E oncoprotein. *Oncogene* **2006**, *25*, 6262-6276.
- (78) Audrito, V.; Messana, V. G.; Moiso, E.; Vitale, N.; Arruga, F.; Brandimarte, L.; Gaudino, F.; Pellegrino, E.; Vaisitti, T.; Riganti, C.; Piva, R.; Deaglio, S. NAMPT over-expression recapitulates the BRAF inhibitor-resistant phenotype plasticity in melanoma. *Cancers* **2020**, *12*, 3855.
- (79) Brandl, L.; Hartmann, D.; Kirchner, T.; Menssen, A. Expression of n-MYC, NAMPT and SIRT1 in basal cell carcinomas and their cells of origin. *Acta Derm.-Venereol.* **2019**, *99*, 63-71.
- (80) Tu, T.; Huang, J.; Lin, M.; Gao, Z.; Wu, X.; Zhang, W.; Zhou, G.; Wang, W.; Liu, W. CUDC-907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2. *Int. J. Mol. Med.* **2019**, *44*, 1789-1800.
- (81) Won, Y.-S.; Kim, J.-H.; Lizardo, R. C. M.; Min, H.-J.; Cho, H.-D.; Hong, S.-M.; Seo, K.-I. The flavonol isoquercitrin promotes mitochondrial-dependent apoptosis in SK-Mel-2 melanoma cell via the PI3K/AKT/mTOR pathway. *Nutrients* **2020**, *12*, 3683.
- (82) Pisano, M.; Palmieri, G.; Rozzo, C.; Dettori, M. A.; Fabbri, D.; Delogu, G. Anticancer Activity of Two Novel Hydroxylated Biphenyl Compounds toward Malignant Melanoma Cells. *Int J Mol Sci* **2021**, *22*.
- (83) Murahari, M. S.; Yergeri, M. C. Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer. *Clin. Cancer Drugs* **2014**, *1*, 127-148.
- (84) Han, X.; Han, Y.; Zheng, Y.; Sun, Q.; Ma, T.; Dai, L.; Zhang, J.; Xu, L. Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies. *OncoTargets Ther.* **2018**, *11*, 1-10.
- (85) Tang, H.; Wu, W.; Fu, S.; Zhai, S.; Song, Y.; Han, J. Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis. *J. Am. Acad. Dermatol.* **2017**, *77*, 480-488.e489.
- (86) Vogeley, C.; Esser, C.; Tueting, T.; Krutmann, J.; Haarmann-Stemmann, T. Role of the aryl hydrocarbon receptor in environmentally induced skin aging and skin carcinogenesis. *Int. J. Mol. Sci.* **2019**, *20*, 6005.
- (87) Chen, C.; Li, Y.; Hou, S.; Bourbon, P. M.; Qin, L.; Zhao, K.; Ye, T.; Zhao, D.; Zeng, H. Orphan nuclear receptor TR3/Nur77 biologics inhibit tumor growth by targeting angiogenesis and tumor cells. *Microvasc. Res.* **2020**, *128*, 103934.
- (88) Brozyna, A. A.; Brozyna, A. A.; Jozwicki, W.; Jozwicki, W.; Jetten, A. M.; Slominski, A. T.; Slominski, A. T. On the relationship between VDR, ROR α and ROR γ receptors expression and HIF1- α levels in human melanomas. *Exp Dermatol* **2019**, *28*, 1036-1043.
- (89) Brozyna, A. A.; Jozwicki, W.; Brozyna, A. A.; Jozwicki, W.; Skobowiat, C.; Jetten, A.; Slominski, A. T.; Slominski, A. T.; Slominski, A. T. ROR α and ROR γ expression inversely correlates with human melanoma progression. *Oncotarget* **2016**, *7*, 63261-63282.
- (90) Aranha, E. S. P.; Portilho, A. J. d. S.; Bentes de Sousa, L.; da Silva, E. L.; Mesquita, F. P.; Rocha, W. C.; Araujo da Silva, F. M.; Lima, E. S.; Alves, A. P. N. N.; Koolen, H. H. F.; Montenegro, R. C.; Vasconcellos, M. C. d. 22 β -hydroxytingenone induces apoptosis and suppresses invasiveness of melanoma cells by inhibiting MMP-9 activity and MAPK signaling. *J. Ethnopharmacol.* **2021**, *267*, 113605.
- (91) Wang, M.; Yue, Z.; Paus, R.; Ramot, Y. SIRT2 as a new player in epigenetic programming of keratinocyte differentiation and a candidate tumor suppressor. *Exp. Dermatol.* **2014**, *23*, 636-638.
- (92) Nair, P. P. S.; Chandrashekarappa, K. K. H.; Masagalli, J. N.; Nagaraja, P.; Mahadevan, K. M. Toxicity and molecular docking studies of tetrahydroquinolines against microbial, cancer, retinoic acid receptor, inflammatory, cholesterol ester transferases and parasitic protein receptors. *Int. J. Pharm. Pharm. Sci.* **2015**, *7*, 448-459.
- (93) Daina, A.; Michielin, O.; Zoete, V. iLOGP: A Simple, Robust, and Efficient Description of n-Octanol/Water Partition Coefficient for Drug Design Using the GB/SA Approach. *J. Chem. Inf. Model.* **2014**, *54*, 3284-3301.

- (94) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Delivery Rev.* **2001**, *46*, 3-26.
- (95) Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases. *J. Comb. Chem.* **1999**, *1*, 55-68.
- (96) Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. *J. Med. Chem.* **2002**, *45*, 2615-2623.
- (97) Egan, W. J.; Merz, K. M., Jr.; Baldwin, J. J. Prediction of Drug Absorption Using Multivariate Statistics. *J. Med. Chem.* **2000**, *43*, 3867-3877.
- (98) Muegge, I.; Heald, S. L.; Brittelli, D. Simple selection criteria for drug-like chemical matter. *J. Med. Chem.* **2001**, *44*, 1841-1846.
- (99) Brzozowska, B.; Lundholm, L.; Brzozowska, B.; Galecki, M.; Tartas, A.; Ginter, J.; Kazmierczak, U. Freeware tool for analysing numbers and sizes of cell colonies. *Radiat Environ Biophys* **2019**, *58*, 109-117.
- (100) Vickers, C. J.; Gonzalez-Paez, G. E.; Wolan, D. W. Selective Detection and Inhibition of Active Caspase-3 in Cells with Optimized Peptides. *J. Am. Chem. Soc.* **2013**, *135*, 12869-12876.
- (101) Liu, D.; Tian, Z.; Yan, Z.; Wu, L.; Ma, Y.; Wang, Q.; Liu, W.; Zhou, H.; Yang, C. Design, synthesis and evaluation of 1,2-benzisothiazol-3-one derivatives as potent caspase-3 inhibitors. *Bioorg. Med. Chem.* **2013**, *21*, 2960-2967.
- (102) Zhang, S.; Nie, S.; Huang, D.; Feng, Y.; Xie, M. A Novel Polysaccharide from *Ganoderma atrum* Exerts Antitumor Activity by Activating Mitochondria-Mediated Apoptotic Pathway and Boosting the Immune System. *J. Agric. Food Chem.* **2014**, *62*, 1581-1589.
- (103) Liu, H.; Li, Z.; Huo, S.; Wei, Q.; Ge, L. Induction of G0/G1 phase arrest and apoptosis by CRISPR/Cas9-mediated knockout of CDK2 in A375 melanocytes. *Mol. Clin. Oncol.* **2020**, *12*, 9-14.
- (104) Syed, D. N.; Lall, R. K.; Chamcheu, J. C.; Haidar, O.; Mukhtar, H. Involvement of ER stress and activation of apoptotic pathways in fisetin induced cytotoxicity in human melanoma. *Arch. Biochem. Biophys.* **2014**, *563*, 108-117.
- (105) Guy GP, M. S., Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the US, 2002–2006 and 2007–2011. *Am J Prev Med* **2015**, *48*, 183–187.
- (106) Guy GP, T. C., Thompson T, Watson M, Massetti GM, Richardson LC. Vital signs: Melanoma incidence and mortality trends and projections—United States, 1982–2030. *MMWR Morb Mortal Wkly Rep.* **2015**, *64*, 591-596.
- (107) RS, S. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. *Arch Dermatol.* **2010**, *146*, 279-282.
- (108) Rheinwald, J. G.; Beckett, M. A. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. *Cancer Res* **1981**, *41*, 1657-1663.
- (109) Gfeller, D.; Grosdidier, A.; Wirth, M.; Daina, A.; Michielin, O.; Zoete, V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. *Nucleic Acids Res.* **2014**, *42*, W32-W38.
- (110) Daina, A.; Michielin, O.; Zoete, V.; Michielin, O.; Michielin, O. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci Rep* **2017**, *7*, 42717.
- (111) Meng, X.-Y.; Zhang, H.-X.; Mezei, M.; Cui, M. Molecular docking: A powerful approach for structure-based drug discovery. *Curr. Comput.-Aided Drug Des.* **2011**, *7*, 146-157.
- (112) Kim, S.; Thiessen, P. A.; Bolton, E. E.; Chen, J.; Fu, G.; Gindulyte, A.; Han, L.; He, J.; He, S.; Shoemaker, B. A.; Wang, J.; Yu, B.; Zhang, J.; Bryant, S. H. PubChem substance and compound databases. *Nucleic Acids Res.* **2016**, *44*, D1202-D1213.
- (113) Burley, S. K.; Berman, H. M.; Christie, C.; Duarte, J. M.; Feng, Z.; Westbrook, J.; Young, J.; Zardecki, C. RCSB Protein Data Bank: Sustaining a living digital data resource that enables breakthroughs in scientific research and biomedical education. *Protein Sci.* **2018**, *27*, 316-330.

- (114) Harris, R.; Olson, A. J.; Goodsell, D. S. Automated prediction of ligand-binding sites in proteins. *Proteins: Struct., Funct., Bioinf.* **2008**, *70*, 1506-1517.
- (115) Forli, S.; Huey, R.; Pique, M. E.; Sanner, M. F.; Goodsell, D. S.; Olson, A. J. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. *Nat. Protoc.* **2016**, *11*, 905-919.
- (116) Trott, O.; Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* **2010**, *31*, 455-461.
- (117) Rigsby, R. E.; Parker, A. B. Using the PyMOL application to reinforce visual understanding of protein structure. *Biochem. Mol. Biol. Educ.* **2016**, *44*, 433-437.

Ref 107: Stern RS. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. *Arch Dermatol.* 2010 Mar;146(3):279-82.